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ABSTRACT 
Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of 
esophageal cancer, a highly fatal malignant neoplasm. Most ESCC patients are diagnosed at a 
late stage when tumors are unresectable or have metastasized. The median survival is less 
than one year, highlighting a great need for early diagnosis and preventive measures. The 
overall aim of the thesis is to provide a better knowledge of how ESCC can be prevented.  
Study I is an incidence study based on the data collected directly from 30 cancer registries in 
20 countries for 1970-2015. Cross-sectional analyses of the year 2012 showed that the 
highest incidence rate of ESCC was in Japan (9.7/100,000 person-years). The incidence had 
decreased continuously in men globally but slightly increased in women from Japan, the 
Netherlands, New Zealand, Norway, and Switzerland. Age-period-cohort analyses revealed 
that birth-cohort effects were strong determinants for the incidence trends. 
Study II is a systematic review and meta-analysis assessing tobacco smoking cessation and 
risk of ESCC. We found 41 relevant studies from 15,009 publications. The random-effects 
model was applied to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs). 
Compared with current smokers, those who stopped smoking 5-9 years earlier had a 
decreased risk of ESCC (RR 0.59, 95% CI 0.47-0.75), and the risk reduction was stronger in 
those who had stopped smoking 10-20 years earlier and reached almost the level of 
nonsmokers in those who had stopped smoking >20 years ago (RR 0.34, 95% CI 0.25-0.47). 
Thus, smoking cessation seems to reduce the risk of ESCC strongly.   
Study III is a Swedish nationwide population-based cohort study in 2005-2015. Among 8.4 
million participants, we identified 411,603 metformin users for the study who were compared 
with ten times as many age- and sex-matched nonusers of metformin. Hazard ratios (HRs) 
were estimated using multivariable cause-specific proportional hazards modeling. The ESCC 
incidence rate was 3.5/100,000 person-years in metformin users and 5.3/100,000 person-
years in nonusers. Compared with nonusers, ever-users of metformin had an HR of 0.68 
(95% CI 0.54-0.85) and new metformin users had an HR of 0.44 (95% CI 0.28-0.64). Thus, 
metformin use may prevent ESCC. 
Study IV is a Swedish nationwide case-control study in 1995-1997, including 167 ESCC 
cases and 820 randomly selected control participants who were all personally interviewed. A 
risk prediction model was developed based on the predictors: age, sex, smoking, alcohol use, 
education, duration of the partnership, and childhood residence. The area under the receiver 
operating characteristic curve was 0.81 (95% CI 0.77-0.84). With these predictors, an 
individual’s absolute risk of ESCC within the next five years can be predicted. 
In summary, this thesis indicates that ESCC remains common cancer globally, that 
prevention of this tumor may be possible by smoking cessation and metformin use, and those 
high-risk individuals can be identified by a risk prediction model, which may enable earlier 
tumor detection.   
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1 INTRODUCTION 
Esophageal cancer has an aggressive nature and poor prognosis. In 2018, esophageal cancer 
was the sixth leading cause of cancer-related deaths and the seventh most common cancer 
worldwide. More than 572,000 new esophageal cancer cases and 508,000 deaths were 
estimated that year. Esophageal squamous cell carcinoma (ESCC) is the predominant (87%) 
histological type of esophageal cancer globally. Early-stage ESCC patients are usually 
asymptomatic, and more than half of the patients first present with unresectable or metastatic 
disease when the prognosis is dismal. Better outcomes in ESCC patients are strongly related 
to diagnosis at an early stage, and in tumor stage I, a five-year survival rate of 80-90% is 
expected. Despite many efforts to advance the treatments during the last decades, the 
prognosis is still poor, with only a 10-20% overall five-year survival rate. 
This thesis contains four studies, focusing on the possibilities of prevention and early 
detection of ESCC. In the first study, we examined the ESCC incidence worldwide and 
analyzed its time trends using the age-period-cohort method. In the second study, we assessed 
the influence of smoking cessation on the risk of ESCC. The third study investigated how 
metformin use (chemoprevention) influences the risk of ESCC. Finally, in the fourth study, 
we developed a risk prediction model for ESCC to help estimate an individual’s absolute risk 
and facilitate early tumor detection.   
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2 BACKGROUND 
2.1 ESOPHAGUS ANATOMY AND ESOPHAGEAL CANCER 
2.1.1 Structure and function of the esophagus 
The adult human esophagus is an 18-25cm long and relatively straight muscular tube through 
which food passes from the pharynx to the stomach. Anatomically, starting from the 
pharyngoesophageal junction in the neck (C5-6 vertebral level), it descends posteriorly to the 
trachea and anteriorly to the spinal column through the mediastinum.1 The esophagus further 
traverses the diaphragm at the hiatus (T10 vertebral level) and extends through the 
gastroesophageal junction to the cardia of the stomach at the T11 vertebral level. Esophageal 
sphincters are located at both the upper and lower ends of the esophagus and prevent food 
backflow. Peristalsis is maintained by contractions of the muscles in the esophageal wall, 
which is composed of four layers: mucosa, submucosa, muscularis propria, and adventitia 
(but without serosa layer).2 The esophageal lumen is normally lined with squamous 
epithelium and shows as a smooth and pale pink tube under endoscopy, with visible 
submucosal blood vessels.  
2.1.2 Esophageal cancer 
2.1.2.1 History  
Although without specific mention of esophageal cancer, the earliest description of this 
disease could trace back to around 3000 BC, as “a gaping wound of the throat penetrating the 
gullet” from the Smith Surgical Papyrus in Egypt.3 Over 2000 years ago, a clear description 
of esophageal cancer appeared in China, referred to as “Ye Ge”, which means dysphagia and 
belching. In the ancient Chinese medical literature, this tumor was believed to be a distinct 
disease caused by “heavy indulgence of heated liquors”, more commonly seen in the elderly 
with dysphagia and having a poor prognosis with less than one-year survival after diagnosis.4 
Centuries later, the Greek physician Galen noticed fleshy growths obstructing the esophagus 
that caused cachexia and death.5 However, it was not until the 11th century that the Arab 
physician Avicenna described the esophageal tumor as one of the causes of dysphagia.5  
During the late renaissance, physicians started documenting esophageal cancer cases to 
collect more medical knowledge. In 1543, the Flemish anatomist Vesalius published the first 
influential anatomy book De humani corporis fabrica, clearly describing the anatomy of the 
esophagus. In the following centuries, the invention of microscopy and the advent of 
pathology prompted a deeper understanding of esophageal cancer. In the 19th century, several 
studies started to link esophageal cancer with risk factors, such as heavy alcohol drinking, not 
the least of absinthe, the most popular alcoholic beverage during that time.6 7 In 1868, the 
development and application of the first esophagoscopy by Adolf Kussmaul enabled direct 
observation of a living esophagus and pathological diagnostics. The following decades 
witnessed a great progress in the surgical treatments of esophageal cancer, including the first 
resection of the cervical esophagus in 1877, the first esophagectomy in 1913, and 
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esophagectomy with intrathoracic esophagogastric anastomosis in 1929.5 Surgery was 
considered as the only curative treatment option for esophageal cancer patients until mid-
1980s when the concept of “multimodality treatment” was introduced by Vincenz Czerny, 
adding radiotherapy and chemotherapy to the surgical treatment. Nowadays, new therapeutic 
methods are practiced in clinics, such as minimal invasive esophagectomy, targeted therapy, 
and immunotherapy.  
2.1.2.2 Histopathology 
There are a few rare histological types of malignant esophageal tumors, e.g., mucoepidermoid 
carcinoma, endocrine tumors, gastrointestinal stromal cell tumors, small cell carcinoma, 
lymphoma, and melanoma, but the two dominating histological subtypes are ESCC and 
esophageal adenocarcinoma (EAC). These two are different entities, considering disease 
distribution, demographics, etiology, pathogenesis, treatment, and prognosis.8 ESCC occurs 
anywhere in the esophagus but is more commonly seen in the distal and middle third of the 
esophagus, while EAC occurs in the distal segment. ESCC develops from the native 
squamous epithelial cells lining the esophagus that might result from local injury and 
inflammation, hyperplasia, and dysplasia, while EAC arises through the replacement of 
squamous epithelium to columnar epithelium by intestinal metaplasia (entitled Barrett’s 
esophagus).8 Well-differentiated ESCC usually contains keratinocytes, accompanied by 
intercellular bridges and keratin, whereas poorly-differentiated ESCC is characterized by the 
presence of intraepithelial neoplasia, in situ lesions in adjacent squamous mucosa, and 
squamous-oriented infiltration. Differentiation grades of EAC are mainly determined by the 
amount of gland formation and the nuclear atypia.8  
 
Figure 1. Estimated age-standardized incidence rate of esophageal cancer worldwide in 2018        
Reproduced with permission from the International Agency for Research on Cancer (IARC).9 
An overview of the incidence of esophageal cancer worldwide in 2018 is shown in Figure 1. 
Although a shift of in the incidence of ESCC has been observed in recent decades with an 
  5 
increasing incidence of EAC and a decreasing incidence of ESCC in several developed 
countries, ESCC remains the predominant histological type worldwide, accounting for 87% 
of all esophageal cancer cases.10 This thesis focuses on ESCC. 
 
2.2 CLINICAL ASPECT OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA 
2.2.1 Diagnosis 
2.2.1.1 Clinical symptoms 
Typical clinical symptoms of ESCC usually present at a late stage when the tumor has 
already invaded more than 60% of the esophageal circumference and is clearly visible at 
endoscopy.11 12 The most common symptoms when first diagnosed are progressive dysphagia 
occurring among 74% of cases, followed by progressive and involuntary weight loss among 
57% of ESCC patients, and odynophagia (pain on swallowing) among 17% of cases.13 
Dysphagia could also be accompanied by radiated pain of the chest or back, and aspiration 
pneumonia. Typically, progressive and involuntary weight loss is reported and is an 
independent predictor of poor prognosis.14 Other less common symptoms include coughing, 
hoarseness, dyspnea, and retrosternal pain, indicating the presence of locally advanced tumor 
growth and invasion of surrounding tissues and organs.15 Some patients develop 
tracheoesophageal fistulas and hypercalcemia without osseous metastases.11 Advanced ESCC 
usually metastasizes to the supraclavicular lymph nodes (including Virchow’s node), liver, 
lungs, pleura, and skeleton. 
2.2.1.2 Diagnosis and staging  
Esophageal squamous dysplasia is regarded as the precursor of ESCC.16 17 ESCC develops 
through multiple pathological alterations from the normal esophagus or low-grade 
intraepithelial neoplasia (mainly esophagitis or basal cell hyperplasia), to middle- or high-
grade intraepithelial neoplasia (i.e., squamous dysplasia or cancer in situ without lamina 
propria invasion), and finally invasive carcinoma.18 Depending on the individual ESCC risk 
pattern, patients with low-grade intraepithelial neoplasia are recommended regular follow-ups 
with endoscopy, while high-grade intraepithelial neoplasia is often treated with endoscopic 
mucosal resection (EMR) or endoscopic submucosal dissection (ESD).19 Individuals with 
high-grade squamous dysplasia and cancer in situ have significantly higher risks of 
developing ESCC compared with low-grade intraepithelial neoplasia, indicating that 
screening for precursors of ESCC might be justified in high-risk populations.16  
The standard diagnostic method of ESCC is white light esophagogastroduodenoscopy with 
biopsies for histopathologic examination and confirmation.14 20 Recent research has found 
that the sensitivity of finding early lesions can be increased from 55% using white light 
endoscopy to 92% using the chromoendoscopy with Lugol’s iodine, and the narrow-band 
imaging system could further improve the sensitivity to 97%.21 22 For poorly differentiated 
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tumors, immunehistochemical staining is recommended by the World Health Organization 
(WHO) to distinguish ESCC from EAC and other histological types of esophageal 
malignancies or secondary tumors.23 Following pathological diagnosis, accurate staging is 
crucial for selecting the most appropriate treatment, and for adequate assessment of the 
prognosis. Staging includes the use of separate or combined diagnostic methods such as 
contrast-enhanced computerized tomography, positron emission tomography, endoscopic 
ultrasound, and sometimes also diagnostic laparoscopy or thoracoscopy.14 24 Specific 
meticulous examinations of the oral cavity, oropharynx, and hypopharynx, and trachea-
bronchoscopy investigation are recommended for some ESCC patients depending on the 
results of the primary assessment.23 The TNM staging system is commonly applied for ESCC 
staging worldwide, taking into account the depth of the primary lesion (T0-4), the 
involvement of lymph nodes (N0-3) and distant metastasis (M0-1).14 The latest version of 
TNM staging (version 8) is shown in Supplementary Table 1, and the illustration of T and N 
category is shown below in Figure 2.  
 
Figure 2. Illustration of TNM staging of esophageal cancer by Yi Zheng                                                                                                                                                                                                                         
2.2.2 Treatment  
Various approaches have been used to treat ESCC, and the treatment differs mainly 
depending on the tumor stage and fitness of the patient.19 Common therapies include 
endoscopic treatment for very early lesions, surgery (esophagectomy) with or without 
neoadjuvant and adjuvant therapy, definitive chemotherapy and/or radiotherapy, as well as 
palliative therapy (e.g., stenting, brachytherapy, chemotherapy, external radiotherapy). Novel 
therapies using immune checkpoint inhibitors are attempted in several ongoing clinical trials, 
showing some promising early results in ESCC patients.25 A multidisciplinary assessment of 
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disease status and treatment options has been proven to improve the clinical decision-making 
and is therefore widely recommended.23 26 
2.2.2.1 Endoscopic treatment 
Endoscopic treatment is applicable in patients with early-stage ESCC (Tis and T1a) with no 
evidence of lymph node metastasis.23 EMR or ESD, radiofrequency ablation or cryoablation 
therapy, and photodynamic therapy are the most commonly used methods.27 28 Combination 
of EMR and radiofrequency ablation seems to be particularly effective in the prevention of 
cancer progression in patients with dysplasia.27 ESD has a higher en bloc resection rate (97% 
vs. 49%) and a higher curative resection rate (92% vs. 53%) than EMR.29 30 Endoscopic 
surveillance following endoscopic treatment is needed due to potential local tumor 
recurrence, metachronous ESCC, or associated head and neck squamous cell carcinoma.31 
2.2.2.2 Curative surgery and neoadjuvant therapy 
For most T1b tumors, esophagectomy is recommended because of the higher rates of lymph 
node involvement than T1a tumors, resulting in a higher risk of local or distant recurrence.28 
Moreover, esophagectomy is widely used in patients with T2N0 tumors and also in patients 
with early-stage tumors whenever endoscopic treatment has failed. Surgery is usually 
combined with neoadjuvant therapy for more locally advanced tumors.32 Common surgical 
procedures are the thoracoabdominal or transhiatal approaches with open or minimally 
invasive techniques.33 Lymphadenectomy is recommended for ESCC patients because of the 
high frequency of lymph node metastasis. However, evidence from large cohort studies 
indicates that a tailored and moderate lymphadenectomy is sufficient.34 35 Neoadjuvant 
chemotherapy or neoadjuvant chemoradiotherapy is a standard therapy for locally advanced 
ESCC.36 A landmark prospective randomized clinical trial (the JCOG9907 trial) focused 
specifically on ESCC and found a significantly decreased hazard ratio (HR) of five-year 
mortality by 0.73 (95% CI 0.54-0.99) in the neoadjuvant chemotherapy group than in the 
adjuvant chemotherapy group in patients with stage II/III ESCC.37  
2.2.2.3 Chemotherapy and radiotherapy  
More and more studies indicate limited or no survival benefits of additional surgery to treat 
ESCC patients with a complete response to chemotherapy or chemoradiotherapy.38 39 A 
Cochrane review concluded that there is sufficient and high-quality evidence to show no 
significant improvement in survival by adding surgery.40 Chemoradiotherapy (cisplatin+5-
fluorouracil +50Gy) has been reported to be superior to radiotherapy alone (64Gy) in locally 
advanced ESCC,41 and oxaliplatin-based and cisplatin-based definitive chemoradiotherapy 
has similarly positive effects.42 Studies examining the intensification of radiotherapy dosing 
for ESCC are ongoing (NCT02741856, NCT02551458). Definitive chemoradiotherapy could 
be a nonsurgical option for locally advanced ESCC patients who are unfit for surgery. For 
unresectable or metastatic ESCC patients, it is also a treatment option for down-staging to 
make the tumor resectable. However, more than 40% of patients fail after definitive 
chemoradiotherapy, and these patients might need salvage surgery.43 
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2.2.3 Prognosis 
More than half of ESCC patients have a late presentation to healthcare and are diagnosed at 
an advanced stage. The global overall five-year survival rate of ESCC was lower than 10-
20% during the recent decade, ranging from 95% for stage 0 disease (cancer in situ) to 10-
15% for stage III disease and less than 5% for stage IV.15 44 The population-based five-year 
overall survival rate of ESCC patients in Sweden is 10.3%.45 Independent prognostic 
predictors of ESCC are tumor stage, sub-site location, weight loss (>10%), patients’ 
performance status, health-related quality of life, and comorbidity.15 32 46 47 
 
2.3 EPIDEMIOLOGICAL ASPECT OF ESOPHAGEAL SQUAMOUS CELL 
CARCINOMA 
2.3.1 Incidence 
In 2018, approximately 572,000 new cases of esophageal cancer occurred worldwide, making 
it the seventh most common cancer.48 As stated earlier, ESCC accounts for 87% of all 
esophageal cancer cases.10 Its incidence varies greatly in different geographic regions, with a 
more than tenfold difference between some countries.10 The highest ESCC incidence areas 
include southern Europe, Eastern and Southern African, and the so-called “esophageal cancer 
belt”, which runs from Northeastern Iran through Central Asia to North-Central China.32 49 
More than half of all ESCC cases (53%) globally occur in China.10 There are also marked 
differences in ESCC incidence within the same country. For example, in China, the ESCC 
incidence in Cixian is 18-fold higher than that in Shanghai.50 The ESCC incidence has been 
reported to be as high as over 100/100,000 person-years in North Central Taihang Mountain 
area, while the Chinese national average rate is around 13/100,000 person-years.50 51  
ESCC is more common in men than women (overall global male-to-female ratio of 2.7).10 
The highest male-to-female ratio is in Eastern Europe at 7.8, and the lowest is in Northern 
Africa and Western Asia at 1.2.10 The sex difference in ESCC is at least partly explained by 
the distribution of etiological factors. Tobacco smoking and heavy alcohol consumption 
greatly increase the risk of ESCC in Western populations,52 53 and the prevalence of smoking 
and alcohol overconsumption is much higher in men than women in most countries.54 With 
the converging smoking behavior between the sexes, the male-to-female ratio decreased from 
2.93 to 2.25 in the United States between 1975 and 2004.55 However, in some high-risk areas 
(e.g., China), smoking and alcohol overconsumption are more similarly distributed among 
men and women and cannot readily explain the sex ratio difference. Thus, other risk factors 
could play a stronger role in these countries.  
The racial disparities are substantial in ESCC. In 2013, the ESCC incidence was 3.3-fold 
higher in black men and 1.9-fold higher in Asian/Pacific Islander men compared to non-
Hispanic white men in the United States.56 Compared with native Asian populations (e.g., 
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Korean), the incidence of ESCC is much lower in Asian immigrants in the United States, 
indicating a strong influence of environmental risk factors in ESCC development.57  
Over the last few decades, alterations in the incidence of esophageal cancer subtypes have 
been witnessed. In some Western countries, e.g., the United States, Australia, and some 
countries in North-Western Europe, the incidence of ESCC has declined, whereas the 
incidence of EAC has increased and now exceeds the incidence of ESCC, especially in 
men.10 58 ESCC is still predominant among women in these countries, and an increasing trend 
has even been predicted in some countries, e.g., Australia, Denmark, and Switzerland.10 59 In 
Southern and Eastern Europe, Asian and African countries, ESCC represents more than 80% 
of all esophageal cancer cases, and in China and Japan, ESCC is almost the exclusive 
histological type of esophageal cancer.51 In Japan, the incidence of ESCC has increased 
during the last decades.54 ESCC is usually easy to distinguish from EAC histologically. Thus, 
misclassification of these tumors is unlikely to explain the reported changes in incidence.  
2.3.2 Etiology  
The etiological factors of ESCC vary among populations. In Western countries, the strongest 
risk factors for ESCC are tobacco smoking and heavy alcohol consumption. These two 
factors together can explain 78% of all ESCC cases in men, and a strong positive synergistic 
effect of tobacco smoking on alcohol use has been identified.60 However, in high-incidence 
areas, e.g., the “esophageal cancer belt” countries, these exposures play less important roles 
in ESCC etiology. Several other risk factors have been identified, which include low intake of 
vegetables and fruits, consumption of red/processed meat and pickled vegetables, nutritional 
deficiencies, intake of very hot food/drinks, and low socioeconomic status.61 62 Other possible 
risk factors of ESCC are poor oral hygiene, human papillomavirus infections, and exposure to 
environmental polycyclic aromatic hydrocarbons.61 More information on risk factors is 
presented in Table 1. Yet, the knowledge of ESCC etiology is still limited, especially in high 
incidence areas.    
2.3.2.1 Tobacco smoking  
Tobacco smoking has a strong association with increased risk of ESCC, particularly in 
Western countries. Smoking alone can contribute to 65% of all ESCC cases in white men in 
the United States, but only 18% of cases in Chinese men.63 64 Several case-control studies 
have reported three to five times higher risk of ESCC among current smokers than among 
never smokers.65 66 These findings have been supported by cohort studies.67 Dose-response 
associations between pack-years of tobacco smoking and ESCC have also been established.67 
68 Interestingly, longer duration of low-intensity tobacco smoking has been found to be worse 
than shorter duration with more intensive tobacco smoking.65 67 An increased ESCC risk has 
also been found among passive smokers.69 Nitrosamines and polycyclic aromatic 
hydrocarbons are believed to be the main carcinogenic agents in the contents of tobacco 
smoke, regardless of tobacco smoking patterns.70 
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Table 1. Risk factors for ESCC 
Risk factor Evidence Comments 
Tobacco smoking ++ Types of tobacco, linear dose-dependence  
Alcohol consumption ++ Types of alcohol, J-shape dose-dependence  
Low fruits and 
vegetable consumption + The effect might be modest 
Red/processed meat + The effect might be modest and confounded by other risk factors 
Picked vegetables + Moderate evidence, only found in Asian countries 
Hot food/drinks + The effect differed with different temperatures and populations 
Low socioeconomic 
status + 
Consistent risk factor but is complicated, may represent 
different perspectives of other factors 
Nutritional deficiencies + Could be confounded by socioeconomic status 
Betel quid + Confirmed risk factor by IARC, positive synergistic effects with tobacco smoking 
Tylosis + Genetic abnormality at chromosome 17q25, familial clusters 
Family history of 
cancer + 
Family history of esophageal and head and neck cancer have 
a significantly higher risk 
Polycyclic aromatic 
hydrocarbons + 
Come from foods, beverages, and cooking or heating 
methods, the main carcinogenesis in some high-risk 
populations 
Poor oral hygiene (+) Limited evidence, involved in inflammation and microbiota 
Achalasia (+) High relative risk but a low absolute risk  
HPV infection (+) No strong evidence, cases caused by HPV are low 
H. pylori infection (+) Limited and inconsistent results 
History of thoracic 
radiation (+) 
Dose-related, a higher risk with higher radiation, but a low 
absolute risk 
Caustic injury (+) Inflammation might have distant effects  
Fanconi 
anemia/Plummer 
Vinson Syndrome 
(+) High risk with low incidence rate and low absolute cases 
Reproductive factors (+) Lack of evidence and might be protective by exposure to estrogen 
Gastric atrophy (+) The effect varies in different populations 
Opium (+) Not established 
Low microbiome (+) The effect varies by composition and richness of microbiota 
 ++ Strong evidence  
+ Moderately strong evidence  
(+) Some evidence 
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2.3.2.2 Alcohol overconsumption 
Heavy alcohol consumption increases the risk of ESCC, and the first metabolite acetaldehyde 
has been recognized as a carcinogenic factor. Mutations in two central enzymes, alcohol 
dehydrogenase (ADH1B) and acetaldehyde dehydrogenase (ALDH2), could affect the 
production of acetaldehyde associated with alcohol overconsumption.50 Exposure to alcohol 
alone may contribute to 72% of all ESCC cases in the United States, but only 11% of cases in 
China.71 72 Studies have shown two to five folds increased risk of ESCC among alcohol 
consumers in high-incidence regions, e.g., Asia and South Africa. The risk is six-fold 
increased in European and nine-fold increased in North American alcohol consumers, 
compared with individuals not using alcohol.36 The drinking patterns in these countries could 
be different. A possible J-shaped curve of association has been identified between the amount 
of alcohol consumption and risk of ESCC, with a low risk associated with low-dose of 
alcohol use and substantially higher risk associated with heavy alcohol consumption.63 73 74  
2.3.3 Chemoprevention   
Experimental and clinical studies have indicated preventive effects of ESCC by some groups 
of medications, including aspirin, statins, and metformin.75 
2.3.3.1 Aspirin  
Aspirin is an anti-inflammatory and analgesic medication. Evidence from observational 
studies and clinical trials have revealed that aspirin may reduce cancer risk, notably, cancer of 
the stomach, colon, lung, and breast.76 77 No clinical trial has examined aspirin use in relation 
to ESCC risk, but observational studies have reported a protective effect and a meta-analysis 
study found a 40% decreased risk of ESCC among aspirin users.78 79 A proposed anti-cancer 
mechanism is that aspirin inhibits cyclooxygenase-2 and consequently prohibits the synthesis 
of prostaglandin.76 80   
2.3.3.2 Statin  
Statin is a molecular inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase and is 
used to reduce serum cholesterol levels and thus prevent cardiovascular disease. Recent 
studies have found a potential chemoprevention effect of statins on the risk of developing 
cancer of the stomach, EAC, pancreas, prostate, and colon rectum,75 81 82 but the only study 
examining the effect of statins on ESCC found no inverse association.83 The biologic 
mechanisms for the anti-carcinogenic effects are not clear, but statin acts as a rate-limiting 
enzyme in the mevalonate pathway, resulting in disruption of post-translational modification 
of small guanosine triphosphate proteins, which are crucial for cell growth signal 
transduction, cellular proliferation, and cell death.83    
2.3.3.3 Metformin 
Metformin is widely used in the treatment of type 2 diabetes. It has a good safety profile and 
low risk of side effects. The use of metformin has been reported to counteract colorectal-, 
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breast-, and gastric cancer.84 The anticancer properties could be due to the following effects 
of metformin: 1) activation of liver kinase B1(LKB1)/AMP-activated protein kinase (AMPK) 
pathway, 2) inhibition of cell division and/or promotion of apoptosis, 3) promotion of 
autophagy, 4) down-regulation of circulating insulin, and 5) activation of the immune 
system.85 The few studies that have investigated the influence of metformin on esophageal 
cancer risk have found contradictory results. Cohort studies from Taiwan and the Netherland 
suggested a preventive effect of esophageal cancer by metformin use, while a British case-
control study and another cohort study from Taiwan did not find any association between 
metformin use and esophageal cancer risk.86-89 Unfortunately, none of these studies separated 
ESCC from EAC despite the substantial etiological differences between these histological 
types of esophageal cancer.86-89 Large and prospective studies with long and complete follow-
up are needed to clarify the effect of metformin on the risk of developing ESCC. 
2.3.4 Early detection  
ESCC is a highly lethal disease with a five-year survival rate of less than 20% in developed 
countries and less than 5% in developing countries, despite all new therapeutic technologies 
developed in recent decades.17 Notwithstanding, 80% to 90% of early-stage ESCC patients 
survive after five years, indicating the great survival benefit of early detection of this disease. 
For endemic areas in China, population-based screening programs have been implemented 
and studies have proven their cost-effectiveness in reducing ESCC-related mortality.90 But 
given the low absolute incidence of ESCC in the general population of the United States, a 
population-based screening program has not been advocated by the guidelines from the 
American Gastroenterology Association.91 It is believed that stratifying population risk using 
a valid prediction model and implementing tailored screening programs only for high-risk 
individuals could be a more feasible method.  
2.3.4.1 Screening  
Endoscopic screening for the ESCC precursor esophageal squamous dysplasia and early-
stage ESCC is regarded as a secondary prevention of ESCC.14 To improve both sensitivity 
and specificity of such screening, several novel endoscopic screening modalities other than 
white-light endoscopy have been developed, i.e., Lugol chromoendoscopy, narrow-band 
imaging system, Fuji intelligent chromoendoscopy, transnasal endoscopy, endocytoscopy, 
and high-resolution microendoscopy. However, widespread endoscopic screening is not 
always feasible because of low cost-effectiveness, low tolerance by individuals, and 
physician-dependent diagnostic accuracy.  
Simpler and less expensive non-endoscopic screening modalities have been investigated 
during the last few years, such as esophageal cytology specimens using balloon or sponges 
with or without tissue collection, breath tests using volatile organic compounds, and blood 
markers using autoantibodies (anti-p53), circulating microRNAs, and methylated DNA 
markers.91 However, because of its relatively low sensitivity and specificity, the clinical 
application of these tools is currently uncertain.17   
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2.3.4.2 Prediction model 
An alternative to broad screening programs is risk stratification using prediction models. It 
might identify a limited group at the high absolute risk of ESCC who may benefit from 
endoscopic screening or surveillance, with the aim of detecting ESCC at a pre-invasive or 
curable stage.92-95 A few prediction models have been developed for high incidence countries. 
A study from China tried to identify subjects with esophageal squamous dysplasia based on 
environmental exposures and physical and dental examinations, but the area under the curve 
(AUC) was low (0.58).94 By pooling environmental risk factors with genetic risk factors, a 
moderately accurate prediction model reported an AUC of 0.71.93 A study from Iran included 
all known risk factors in that region and developed a prediction model with a higher AUC of 
0.77.95 All these three studies are hospital-based, and population-based studies are warranted. 
A recently published study used a population-based design in a rural county in China and 
evaluated ESCC risk factors and found an AUC of 0.80 in individuals aged less than 60 years 
and an AUC of 0.68 in those older than 60 years.92 No risk prediction model of ESCC has 
thus far been developed for Western populations. 
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3 AIMS 
The overarching aim of this thesis is to provide knowledge that can contribute to identifying 
better opportunities for the prevention of ESCC by revealing new insights into the etiology, 
chemoprevention, and prediction of this tumor.  
To reach this overarching aim, four studies were conducted with the following specific aims: 
• To assess temporal changes in incidence rates of ESCC globally in order to reveal the 
burden of this cancer and provide clues for its etiology (Study I); 
• To clarify how tobacco smoking cessation influences the risk of ESCC (Study II); 
• To elucidate whether and to which extent that metformin use prevents ESCC (Study 
III); 
• To develop a risk prediction model of ESCC to identify high-risk individuals in a 
Western population who may benefit from endoscopic screening or surveillance to 
facilitate the detection of premalignant lesions and early-stage ESCC (Study IV). 
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4 METHODS 
4.1 OVERVIEW  
Table 2. Methods overview of the included studies  
 Study I Study II Study III Study IV 
Short title Global 
incidence trends 
of ESCC 
Smoking cessation 
and ESCC risk 
Metformin use and 
ESCC risk 
Risk prediction 
model of ESCC 
Design Descriptive 
study 
Systematic review 
and meta-analysis 
Population-based 
cohort study 
Population-based 
case-control study 
Study period 1970-2015 -2016 2005-2015 1995-1997 
Data sources 30 cancer 
registries in 20 
countries 
Medline, Embase, 
Web of Science, 
Cochrane Library, 
ClinicalTrials.gov 
Swedish 
Prescribed Drugs 
and Health cohort 
(SPREDH) 
 
Swedish 
Esophageal and 
Cardia Cancer study 
(SECC) 
 
Participants General 
populations 
From selected 
studies of smoking 
and ESCC risk   
Users of 
commonly 
prescribed 
medications  
Incident ESCC 
patients and cancer-
free control 
participants 
Exposure Time (calendar 
year) 
Smoking status 
and smoking 
cessation 
Metformin use Age, sex, education, 
partnership, 
childhood 
residence, smoking, 
alcohol, 
fruits/vegetables, 
family cancer 
history 
Confounders Age, sex As assessed in the 
included studies 
Age, sex, calendar 
year, smoking, 
alcohol, residence, 
use of non-
steroidal anti-
inflammatory drug 
(NSAID) or 
aspirin, use of 
statin 
Not applicable 
Outcome ESCC incidence ESCC  ESCC ESCC  
Statistical 
analysis 
Age-
standardized 
incidence rates;  
Joinpoint 
analysis; 
Age-period-
cohort analysis 
Random-effects 
meta-analysis; 
Cochran’s Q test 
and I2 statistic 
Cumulative 
incidence 
competing risk 
curve;  
Cause-specific 
proportional 
hazards model 
Unconditional 
logistic regression; 
Prediction modeling 
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4.2 DATA SOURCES  
4.2.1 Cancer registries in 20 countries  
In Study I, the following 30 well-established cancer registries from 20 countries were 
included (in alphabetical order): Asturias Cancer Registry (Spain), Australian Capital 
Territory Cancer Registry (Australia), Cancer Institute New South Wales (Australia), Cancer 
Registry of Norway, Cancer Registry of Republic of Slovenia, Chiang Mai Cancer Registry 
(Thailand), Croatian National Cancer Registry, Finnish Cancer Registry, Granada Cancer 
Registry (Spain), Hong Kong Cancer Registry (China), Icelandic Cancer Registry, Kuwait 
Cancer Registry, Miyagi Prefectural Cancer Registry (Japan), Nagasaki Prefectural Cancer 
Registry (Japan), National Cancer Registry (Ireland), National Institute for Cancer 
Epidemiology and Registration (Switzerland), Netherlands Cancer Registry, New Zealand 
Cancer Registry, Public Health England (United Kingdom), Public Health Wales (United 
Kingdom), Registre des Tumeurs Digestives du Calvados (France), Scottish Cancer Registry, 
South Australian Cancer Registry (Australia), Surveillance Epidemiology and End Results 
Program (United States), Swedish Cancer Registry, Tarragona Cancer Registry (Spain), 
Tasmanian Cancer Registry (Australia), Tumor and Tissue Registry Office Hiroshima 
(Japan), Veneto Tumor Registry (Italy), Western Australian Cancer Registry (Australia). 
The included cancer registries have all shown high completeness and good data quality.96 We 
also assessed the completeness of the histological classification of esophageal cancer in these 
registries and found that unspecified histology was <20% in all included cancer registries, 
except for higher rates in Granada Cancer Registry in Spain (22%) and Chiang Mai Cancer 
Registry in Thailand (30%).  
4.2.2 Publicly available databases  
In Study II, we searched in publicly available databases for relevant published literature, i.e., 
from Medline, Embase, Web of Science, Cochran Library database, and ClinicalTrials.gov. 
We also reviewed the IARC monographs on “Smokeless tobacco and some tobacco-specific 
N-nitrosamines” and “Tobacco smoking and involuntary smoking” to identify additional 
relevant studies.97 98 
4.2.3 The Swedish Prescribed Drugs and Health cohort (SPREDH)  
Study III used data from the SPREDH. It is a registry-based database that started on July 1, 
2005, which contains 8.4 million people with records of selected commonly-used drugs.99 
SPREDH includes data from the following four national registries and participants are linked 
between registries by the personal identity number, a unique identifier in all Swedish 
residents.  
4.2.3.1 The Swedish Prescribed Drug Registry  
The Swedish Prescribed Drug Registry is the primary registry in SPREDH, and it started on 
July 1, 2005, and contains all prescribed and dispensed drugs in all pharmacies in Sweden. 
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The registry attributes to about 84% of total drug prescriptions nationwide. The remaining 
16% is over-the-counter medicines and drugs dispensed in the hospitals. Data on drugs in 
pharmacies are transferred and updated monthly to the Swedish National Board of Health and 
Welfare. The registry records the following information in outpatient care: age, sex, personal 
identity number, place of residence, dispensed medication, data of prescription and 
dispensation, and the prescriber’s profession and affiliated practice clinics or center.100 
Information regarding each dispensed medication includes substance, brand name, 
formulation, package size, amount, dosage, expenditure, and reimbursement. The Anatomical 
Therapeutic Chemical (ATC) classification system is used to classify all medications, with a 
measurement unit of each prescription. Defined Daily Dose (DDD) per package are also 
defined.   
4.2.3.2 The Swedish Patient Registry 
The Swedish Patient Registry covers almost 100% of the Swedish inpatient healthcare since 
1987 and almost 100% of specialized outpatient care given by public caregivers since 2001, 
including day surgery and psychiatric care.99 The overall completeness of the registry is 
around 80% due to missing data from private health caregivers, while the completeness is 
100% for specific diseases (e.g., ESCC) which are not handled in private care.101 The registry 
contains information on age, sex, personal identity number, date of admission and discharge, 
diagnoses, and surgical procedures. The Swedish version of the International Classification of 
Diseases (ICD) system is used to code the diagnoses.  
4.2.3.3 The Swedish Cancer Registry  
The Swedish Cancer Registry was nationwide from its start in 1958 and records data on 
newly diagnosed malignancies among residents in Sweden. The overall completeness for all 
cancer types is about 96%.102 For cancer of the esophagus and cardia, the completeness is 
98%, with a 100% histological confirmation rate,103 and the site-specific completeness is 91% 
for ESCC. The Cancer Registry holds information on age, sex, personal identity number, 
place of residence, basis of diagnosis, anatomic site, histology, stage of the tumor, date of 
diagnosis, and the reporting hospital and department. From 1958, the Swedish version of 
ICD-7 codes and WHO/HS/CAN/24.1 have been used for the anatomic site of the tumor and 
histological type, respectively. From 2005, the Swedish version of ICD-10 was introduced for 
coding of the site of the tumor, and the 3rd version of the International Classification of 
Disease for Oncology (ICD-O-3) was used to code histological types. 
4.2.3.4 The Swedish Cause of Death Registry  
The Swedish Cause of Death Registry has been available for research since the year 1952, 
and it records the date and causes of deaths in Sweden on an annual basis. Before 2011, 
deaths of Swedish residents (who died in or outside Sweden) were recorded, while from 
2012, all deaths in Sweden, including those of non-Swedish residents, are included. Overall, 
the registry has 100% completeness for the date of death and 96% completeness for the 
underlying cause of death.104 The registry includes information on age, sex, personal identity 
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number, place of residence, and underlying and contributing causes of death. ICD-6 was first 
introduced for the registry in 1951, and new versions have been introduced in 1958 (ICD-7), 
1969 (ICD-8), 1987 (ICD-9), and 1997 (ICD-10).  
4.2.4 The Swedish Esophageal and Cardia Cancer study (SECC) 
Study IV used data from SECC, a nationwide population-based case-control study in Sweden 
from December 1, 1994, to December 31, 1997. Eligible participants were those younger than 
80 years old, born in Sweden, and living in Sweden during the study period. The sources of 
ascertainment of control subjects, case patients, and data needed are presented below.   
4.2.4.1 The Registry of the Total Population  
The Registry of the Total Population was used to randomly select population-based control 
subjects. It was founded in 1968 and records data on life events such as date of birth, date of 
death, marital status, family relationships, migration in Sweden, and immigration from and 
emigration to other countries. The registry data is updated daily by the Swedish Tax 
Agency.105 The coverage is virtually 100% of the general population in Sweden.     
4.2.4.2 Case ascertainment   
New esophageal or gastric cardia cancer cases were included by local contact persons at all 
195 hospital departments and six regional cancer centers in Sweden. Half of all ESCC (born 
on even-numbered dates) were eligible. Uniform clinical routines were implemented in all 
these departments to ensure accurate information of the tumor site and histology. Endoscopic 
examination was performed for all patients and 97% of patients’ biopsy samples or surgical 
specimens were re-reviewed by a single experienced pathologist.    
4.2.4.3 Personal interview  
Both control subjects and case patients underwent computer-aided face-to-face interviews in 
their own homes by professional interviewers from Statistics Sweden, who were unaware of 
the study hypotheses and educated to treat all participants equally. Most interviews in case 
patients were conducted within a few weeks after the cancer diagnosis. The average length of 
the interview was 80 minutes with a total number of questions between 169 and 553, 
depending on the answers. The interviews provided information about age, sex, tobacco 
smoking, alcohol consumption, education, fruit and vegetable intake, physical activity, and 
many other variables.   
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4.3 STUDY DESIGN  
4.3.1 Study I 
4.3.1.1 Design 
Study I was a global registry-based descriptive study that explored changes in the incidence 
of ESCC over time using joinpoint analysis and age-period-cohort analysis.  
4.3.1.2 Data collection 
We collected data directly from 30 well-established cancer registries in 20 countries in 
Europe, Northern America, Australia, and Asia. The data covered the period from January 1, 
1970, to December 31, 2015 (varying across registries). The requested data from each cancer 
registry included the number of newly diagnosed ESCC by the calendar year (one-year 
increment), age group (0-80 in five-year increments, and 85+), sex, and the size of the 
corresponding background population. 
For classification of ESCC, most cancer registries used the code C15 in ICD-10 for defining 
esophagus as the site of the tumor, alternatively, the code 150 in ICD-7, ICD-8, or ICD-9 was 
used. The histological codes 8050-8078 or 8083-8084 were used to define squamous cell 
carcinoma in ICD-O-3. 
4.3.1.3 Statistical analysis 
Age-standardized annual incidence rates (ASR) with the gamma distribution confidence 
intervals (CIs) were calculated using the direct method with the WHO World Standard 
Population (2000) as reference.106 We used the joinpoint regression program developed by 
the National Cancer Institute in the United States to identify points overtime where changes 
in the incidence occurred and to estimate the annual percentage change (APC) for each time 
segment before and after the joinpoints.44 The APC in the incidence was computed on a 
relative scale (log-linear) under the assumption that the rate changed at a constant percentage 
linearly on a log scale within a specific period. With the joinpoint model, we calculated a 
weighted average of annual percent change (AAPC) with weights the same as the length of 
the APC interval during the whole observation period. We also performed age-period-cohort 
regression for each sex, to estimate the influence of age, calendar periods, and birth cohorts 
on the observed ESCC incidence rates. Relative rates in any given calendar period (or birth 
cohort), adjusted for age and non-linear cohort (or period) effects were compared with a 
reference period (or birth cohort).  
4.3.2 Study II 
4.3.2.1 Design  
Study II was a systematic literature review and meta-analysis following the PRISMA 
statements and MOOSE guidelines.107 108 This study aimed to estimate the influence of 
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tobacco smoking cessation on the risk of esophageal cancer, with a focus on ESCC, across 
time latencies and geographic regions. 
4.3.2.2 Data collection 
Relevant publications were systematically searched on the publicly available databases listed 
in Section 4.2.2 for studies reporting the association between tobacco smoking and risk of 
esophageal cancer, with three themes of Medical Subject Headings terms and related 
extended versions: “smoking or tobacco”, “esophageal or oesophageal”, and “cancer,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          Figure 3. Flow chart of study selection 
     14,979 records identified 
   7,824 from Medline 
  3,639 from Embase 
                3,204 from Web of Science  
                309 from Cochrane Library 
 
30 additional records identified 
through ClinicalTrials.gov 
11,029 records screened after duplicates removed 
 
1,819 potentially relevant articles identified for 
further full-text review  
9,210 records excluded on the basis of 
screening of title or abstracts 
 
 
 
205 articles met the inclusion criteria 
1,614 articles excluded on the basis of first round of full-  
          text review 
           973  included only relevant exposure (smoking) or  
                      outcome, not both 
           311 were without original data (review, meeting      
                      abstracts, protocol, books, guideline, etc.) 
           101 were lab-related works 
           83 were incidence rate studies 
           77 were duplicates 
           56 were not in English  
           13 were case reports 
41 articles included in the  
meta-analysis for ESCC 
 
23 articles identified from reference lists  
187 articles excluded on the basis of second round of full- 
        text review 
          53 lacked histology information 
          39 used data from the same population 
          31 lacked former smoker data 
          25 were duplicates 
          11 focused only on EAC, but not ESCC 
          8 were pooled analysis without original data  
          5 were not tobacco smoking related 
          4 were not specific esophageal cancer   
          4 used outcome of mortality 
          4 had data unavailable or could not be extracted 
          2 were letters to editors 
          1 used outcome of second primary cancer  
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squamous cell carcinoma or adenocarcinoma”. These three themes were combined with a 
Boolean operator “AND”. Relevant references were also found in original articles, review 
articles, and systematic reports. There were no specific restrictions on the initial screening.  
Inclusion criteria were: 1) studies where relative risk of ESCC associated with smoking status 
can be estimated, 2) observational studies (case-control, cohort, or cross-sectional) or 
interventional studies (randomized clinical trials), and 3) original and independent studies 
with the full texts available. We only included the most recent or most informative 
publication if there were more than one publication from the same population. A detailed 
flow chart of the study selection is shown in Figure 3.  
4.3.2.3 Quality assessment 
Two authors independently evaluated the quality of the identified studies, using a maximal 
ten-points scale including the nine-item Newcastle-Ottawa Scale and an additional item for 
the main exposure (smoking).109 110 The final quality assessment items for case-control 
studies were: case definition, representativeness of cases, selection of controls, definition of 
controls, adjustment for alcohol, adjustment for diet, ascertainment of the exposure, method 
of ascertainment, non-response rate, and smoking as the main exposure. For cohort studies, 
the quality assessment items were: representativeness of the exposed cohort, selection of non-
exposed cohort, ascertainment of the exposure, exclusion of outcome at baseline, adjustment 
for alcohol, adjustment for diet, assessment of the outcome, follow-up for at least ten years, 
less than 20% loss-to-follow-up, and smoking as the main exposure. The study quality score 
ranged from 0 to 10 points, where higher scores represent higher quality. Discrepancies 
between the two evaluators were reviewed together to reach consensus or further assessed by 
a third author.  
4.3.2.4 Statistical analysis 
Risk ratio (RR) was the main measure for the association between smoking cessation (or 
smoking status) and ESCC risk across studies. For studies using HRs and odds ratios (ORs), 
these measures were used as approximate estimates of the RRs value given the low incidence 
rate of ESCC.111 Considering heterogeneity, pooled RR results were computed in the random-
effects model using Der-Simonian and Laird’s method.112  
Statistical heterogeneity was evaluated by Cochrane’s Q statistic with a significant P-value 
defined as <0.1 and I2 statistic, which provided an estimate of the amount of variance across 
studies derived from heterogeneity rather than chance. Stratified analyses and exploratory 
meta-regression were carried out to examine potential sources of study heterogeneity. 
Sensitivity analysis by removing one study at a time was conducted to evaluate the robustness 
of the main results. Publication bias was examined by Begg’s and Egger’s tests as well as 
funnel plots. 
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4.3.3 Study III 
4.3.3.1 Design 
Study III was a nationwide population-based cohort study during the study period from July 
1, 2005, to December 31, 2015. The objective of this study was to test whether use of 
metformin prevents ESCC.  
4.3.3.2 Study cohort 
All residents in Sweden included in the SPREDH cohort were considered for inclusion. The 
exposed group included those who had been dispensed metformin during the study period. 
The entry of the cohort was the date of the first dispensation of metformin. New metformin 
users were defined as those without records of metformin dispensation between July 1, 2005, 
and June 30, 2006 (one-year observation window), but with records of metformin use after 
this year. The unexposed group was those who were randomly sampled from the general 
population in SPREDH and had no metformin dispensation record by the time when the 
matched exposed participants entered the cohort. The unexposed participants were ten times 
as many as the exposed participants and were frequency-matched by age (within one year) 
and sex. Inclusion criteria were those aged 18 years or above with no previous cancer history 
(except for non-melanoma skin cancer) at cohort entry. Participants with metformin 
dispensation records before the age of 18 or with an incongruous date of death were 
excluded. The flowchart of participants’ enrolment is shown in Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Flow chart of participants’ enrolment 
Population in the SPREDH between July 1, 2005 and 
December 31, 2015 (n=8,421,115) 
n=7,612,360 
808,755 were excluded because of age 
below 18 years 
 
Eligible subjects 
(n=7,100,057) 
509,854 were excluded because of 
previous cancer history 
2,133 were excluded because of 
incongruous date of death 
316 were excluded because of metformin 
use before age 18 years 
 
n=7,102,506 
Study cohort (n=4,527,633) 
    Metformin users: n=411,603 
    Matched non-metformin users: n=4,116,030 
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4.3.3.3 Covariates 
Covariates were age, sex, calendar year of study entry, place of residence, smoking-related 
diagnosis (within ten years before study entry), alcohol use-related diagnosis (within ten 
years before study entry), use of NSAIDS or aspirin (within the first year after study entry), 
and use of statin (within the first year after study entry).  
4.3.3.4 Outcome  
The outcome of interest was a new diagnosis of ESCC. All participants were followed up 
until their first diagnosis of ESCC, first metformin dispensation (non-exposed group only), 
death, or end of the study (December 31, 2015), whichever occurred first.   
4.3.3.5 Statistical analysis 
Cumulative incidence competing risk curves with K-sample test were computed for the 
metformin user group and nonuser group. A multivariable cause-specific proportional 
hazards model was used to calculate HRs, treating metformin use as a time-dependent 
covariate. The proportionality assumption was tested using the scaled Schoenfeld residuals. 
Stratified analyses were performed by age at study entry, sex, and calendar period. We 
categorized metformin users into three groups according to the total DDD used during the 
first year of metformin dispensation. A dose-response analysis of metformin use in 
association with the risk of ESCC was conducted. Sensitivity analyses were performed by 1) 
censoring participants who developed any cancer (except the non-melanoma skin cancer) 
before ESCC and 2) excluding participants who were followed up for less than one year, 
regardless of exposure status and reasons for the end of follow-up. To explore unmeasured or 
residual confounding, a rule-out approach analysis was conducted.113   
4.3.4 Study IV 
4.3.4.1 Design  
Study IV provided a risk prediction model based on a nationwide population-based case-
control study (SECC) in Sweden. The aim of the study was to identify individuals of high 
absolute risk of ESCC who may benefit from endoscopic screening or surveillance. 
4.3.4.2 Candidate predictors 
We selected candidate predictors based on a literature review and associations found in 
analyses of data in SECC. Candidate predictors were: age, sex, years of formal education, 
years of living with a partner, area of residence during childhood, tobacco smoking, alcohol 
overconsumption, intake of fruits and vegetables, and history of cancer of the esophagus or 
head and neck in first-degree relatives.  
4.3.4.3 Statistical analysis 
Two models were developed. In a “full model”, well-established risk factors for ESCC were 
included directly, i.e., age, sex, tobacco smoking, alcohol overconsumption, while for other 
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predictors, a stepwise backward selection approach was conducted. Using the likelihood ratio 
test, we re-entered eliminated predictors back to the final model one by one to make sure no 
predictor significantly improved the goodness of fit. In a “simple model”, we only included 
the above four well-established risk factors.  
To test the performance of the models, we assessed its discriminative ability using the AUC 
and Somers’ D statistics.114 To consider the over-fitting, we also assessed the model 
performance with leave-one-out cross-validation.  
An individual’s five-year absolute risk of ESCC was calculated using the relative risk, 
population attributable risk, age- and sex-specific incidence rate of ESCC in the general 
population, and age- and sex-specific mortality rate from competing causes.  
 
4.4 ETHICAL CONSIDERATIONS   
Rigorous ethical considerations have been made for each of the studies included in this thesis, 
including individual consent, confidentiality, security regarding storage, and analysis of 
sensitive data.  
In study I, we only collected tabulated data from different cancer registries without using any 
individual data. In study II, we conducted a systematic review and meta-analysis by pooling 
published results and analyzing the association of smoking cessation and esophageal cancer 
without requesting information of individuals. Therefore, ethical permissions were exempted 
for these two studies.  
In study III, individual information was collected from national registries maintained by the 
governmental agency Swedish National Board of Health and Welfare. In Sweden, individual 
consent is exempt for registry-based research.115 The Swedish National Board of Health and 
Welfare did the linkages between the registries and substituted the personal identity numbers 
with unidentifiable codes before delivering the data. The electronic dataset is stored on a 
university-based secure server, which is backed-up everyday. The derived results were 
interpreted and presented only at the group level, which further ensures anonymization. The 
Regional Ethical Review Board in Stockholm approved this study and the National Board of 
Health and Welfare approved to leave out the data. 
In study IV, individual information was obtained from interviews and medical records, which 
required informed and written consents of the participants. Individual data handled by 
researchers were treated with the utmost confidentiality. Paper copies of medical records 
were stored in safes on locked university premises. All regional ethical review boards in 
Sweden approved the study. 
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5 RESULTS 
5.1 STUDY I 
Study I included 180,395 incident ESCC cases from the 30 registries. Of these, 61% were 
men. The median age at ESCC diagnosis was 67.5 years (interquartile range 62.5-77.5 years). 
During the study period, year 2012 witnessed the highest incidence rate of ESCC in men in 
Japan (9.7/100,000 person-years) and in women in Scotland (2.7/100,000 person-years). The 
male-to-female incidence ratio varied between 9:1 and 1:1 depending on the geographic area. 
 
Figure 5. Global annual age-standardized incidence rates of ESCC in men 
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In men, the incidence of ESCC decreased from year 2000 in most countries with varying 
slopes and joinpoints, but the incidence rates remained high in Japan, France and Hong Kong, 
China (Figure 5). A sharp decline was found in Calvados, France and Hong Kong, China, 
whereas the incidence increased by 1% per year in Japan during 1986-2005. The age-period-
cohort analysis revealed that calendar-period and birth-cohort effects might explain the 
decreasing trends, while the calendar-period effect contributed to the increasing trend in 
Japan (P=0.021).  
 
Figure 6. Average annual percentage change and 95% CI in the incidence of ESCC by sex  
In women, the incidence was stable or decreased in most countries, but increasing trends 
were found in women in Japan, the Netherlands, New Zealand, Norway and Switzerland 
(Figure 6). The age-period-cohort analysis showed a significant calendar-period effect in 
Norwegian women (P=0.046), especially those aged 45-70 years, whereas a birth-cohort 
 
Figure 7. Relative risk for ESCC incidence by birth-cohort in women 
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effect was identified in women from Japan (P<0.001), the Netherlands (P<0.001), and 
Switzerland (P=0.014). Compared with the reference cohorts, the birth-cohort-specific 
relative risk increased in women born after 1945 in Japan and Norway, but not in the 
Netherlands or Switzerland (Figure 7).      
 
5.2 STUDY II  
In Study II, the initial search identified 15,009 publications, of which 41 were selected. 
Among these, 22 (54%) studies were found to be of high quality (score ≥ 7) and 18 (41%) 
reported results for years after smoking cessation.   
Using nonsmokers as a reference, the overall RR of ESCC was higher among current 
smokers (RR 4.18, 95% CI 3.42-5.12) than among former smokers (2.05, 95% CI 1.71-2.45) 
(Table 3). In North America, the risk difference between current smokers (RR of 5.75, 95% 
CI 3.56-9.26) and former smokers (RR of 2.45, 95% CI 1.83-3.27) was largest, while such 
big difference was not found in Asian populations. There were no major sex differences in 
the risk of ESCC among current or former smokers.  
Table 3. Tobacco smoking status and risk of ESCC, using nonsmokers as the reference 
Study 
characteristics 
RR (95% CI) in 
former smokers 
Studies 
(n) 
RR (95% CI) in 
current smokers 
Studies 
(n) 
Overall 2.05 (1.71-2.45) 41 4.18 (3.42-5.12) 41 
Study design     
Case-control 2.01 (1.67-2.43) 37 3.81 (3.06-4.74) 37 
Cohort 2.50 (1.29-4.85) 4 6.95 (4.17-11.57) 4 
Publication year     
≤1999 1.98 (1.54-2.54) 8 5.07 (3.35-7.68) 8 
2000-2009 1.85 (1.47-2.34) 21 3.62 (2.83-4.64) 21 
≥2010 2.57 (1.69-3.91) 12 4.29 (2.54-7.24) 12 
Geographic origin     
North America 2.45 (1.83-3.27) 7 5.75 (3.56-9.26) 7 
Europe 1.75 (1.15-2.65) 14 4.57 (3.19-6.54) 14 
Oceania 2.18 (1.51-3.17) 1 4.58 (2.99-7.02) 1 
Asia 2.47 (1.78-3.44) 12 2.82 (1.81-4.39) 12 
South America 1.67 (1.37-2.04) 7 2.91 (2.41-3.50) 7 
Sex*     
Men 2.00 (1.43-2.80) 10 3.77 (2.29-6.20) 10 
Women 1.34 (0.71-2.53) 6 3.85 (2.20-6.74) 6 
Unspecified 2.26 (1.86-2.76) 29 3.94 (3.12-4.99) 29 
Response rate     
≥80%  1.92 (1.56-2.36) 15 4.21 (2.74-6.47) 15 
<80% 2.42 (1.70-3.45) 10 4.80 (3.09-7.43) 10 
Unknown  1.95 (1.36-2.78) 16 3.51 (2.69-4.60) 16 
Tobacco types     
Cigarettes  2.38 (1.58-3.60) 15 4.02 (3.07-5.28) 15 
Unspecified 1.94 (1.66-2.26) 26 3.96 (2.94-5.33) 26 
Study quality     
Low (score<7) 2.16 (1.63-2.86) 19 3.60 (2.65-4.90) 19 
High (score≥7) 1.97 (1.57-2.48) 22 4.45 (3.31-5.99) 22 
* Two studies (Stefani et al.1990 and Victora et al.2007) reported RR for men and women separately and combined; one study (Kabat et 
al.1993) reported RR for men and women separately. 
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A dose-response association was found between years after smoking cessation and risk of 
ESCC (Figure 8). Compared with current smokers, those who had quit smoking <5 years 
earlier had no decreased risk (RR 0.96, 95% CI 0.73-1.25), while the risk was decreased 
following smoking cessation for 5-9 years (RR 0.59, 95% CI 0.47-0.75), further decreased 
after 10-20 years (RR 0.42, 95% CI 0.34-0.51), and was lowest >20 years after smoking 
cessation (RR 0.34, 95% CI 0.25-0.47). The latter risk estimate was similar to that in never 
smokers (RR 0.22, 95% CI 0.18-0.28).    
 
Figure 8. Risk ratio of ESCC by duration since smoking cessation 
The meta-regression analysis revealed that sex and study quality caused heterogeneity in the 
analysis of former smokers, while study geographic origin and control selection method 
resulted in heterogeneity in the analysis of current smokers. No publication bias was found.  
 
5.3 STUDY III 
Study III included 411,603 metformin users with a mean follow-up time of 6.0 (±3.4 standard 
deviation [SD]) years and 4,116,030 nonusers of metformin who were followed up for a 
mean of 5.8 (±3.5 SD) years.   
 
Figure 9. Cumulative incidence of participants developing ESCC during the follow-up among metformin 
users and nonusers of metformin 
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The incidence rate of ESCC in metformin users and nonusers were 3.5/100,000 person-years 
and 5.3/100,000 person-years, respectively (Figure 9). Its cumulative incidence was 
significantly lower in the metformin user group than in the nonuser group (P<0.001). 
Multivariable cause-specific proportional hazards model revealed an HR of 0.68 (95% CI 
0.54-0.85) in ever metformin users and 0.44 (95% CI 0.28-0.64) in new metformin users 
(Table 4). Sensitivity analyses and the rule-out approach analysis supported the robustness of 
these main results.  
Table 4. Risk of ESCC in metformin users compared with nonusers in Sweden in 2005-2015 
Analysis ESCC (n) Model 1 Model 2 Model 3 
Metformin use  1,348 0.66 (0.53-0.82) 0.67 (0.54-0.84) 0.68 (0.54-0.85) 
New metformin use 627 0.46 (0.32-0.67) 0.46 (0.31-0.67) 0.44 (0.28-0.64) 
Sensitivity analysis 1* 1,210 0.68 (0.54-0.85) 0.69 (0.55-0.87) 0.70 (0.56-0.88) 
Sensitivity analysis 2† 1,142 0.66 (0.52-0.84) 0.67 (0.53-0.85) 0.68 (0.53-0.86) 
Dose-response analyses 
    
≤175 DDD 22 Reference Reference Reference 
175-300 DDD 24 0.94 (0.53-1.68) 0.90 (0.50-1.61) 0.91 (0.51-1.63) 
> 300 DDD 27 0.83 (0.47-1.47) 0.88 (0.49-1.59) 0.89 (0.49-1.61) 
Model 1: crude analysis; Model 2: adjusted by age, sex, calendar year, residence, smoking, and alcohol overconsumption; Model 3: model 2 
further adjusted by non-steroidal anti-inflammatory drugs/aspirin and statin use. * Censored those who developed any other cancers (except 
for non-melanoma skin cancer) before ESCC during follow-up; † Excluded those with less than one-year follow-up, regardless of exposure 
status and reasons for the end of follow-up. 
 
Compared with low-dose (<175 DDD) metformin use in the first year of enrollment, the 
intermediate-dose group (175-300 DDD) and high-dose group (>300 DDD) had slightly 
lower point estimates (HR 0.91, 95% CI 0.51-1.63 and HR 0.89, 95% CI 0.49-1.61, 
respectively) (Table 4).  
 
5.4 STUDY IV 
Study IV included 167 ESCC cases and 820 controls. After the predictor selection strategy, 
six variables remained in the full model: age, sex, tobacco smoking, alcohol 
overconsumption, a combined variable of education years and partnership years, and 
childhood residence. The simple model included age, sex, tobacco smoking, and alcohol 
overconsumption. The population attributable fraction was 0.95 for the full model and 0.85 
for the simple model.  
The full model had an AUC of 0.81 (95% CI 0.77-0.84) and the simple model had an AUC of 
0.79 (95% CI 0.75-0.82) (Figure 10). The leave-one-out cross-validation analysis slightly 
reduced the AUC to 0.78 (95% CI 0.75-0.82) in the full model and 0.75 (95% CI 0.71-0.79) 
in the simple model.  
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Figure 10. Receiver operating characteristic (ROC) curves based on the full model and the simple model 
A heat chart based on the simple model is presented in Figure 11, containing an estimated 
absolute five-year risk in individuals with different risk exposures. In the highest absolute risk 
group (281.4/100,000 person-years), 355 subjects need to be surveyed to identify one case of 
ESCC within five years. Detailed absolute risk calculators for both models are available in 
the online appendixes with the link below: https://doi.org/10.1016/j.gie.2018.10.025   
 
Figure 11. Absolute five-year risk of ESCC per 100,000 person-years, estimated from the simple model in 
individuals aged 50 years or above    
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
This thesis comprises a mix of study designs, i.e., a descriptive study (Study I), a systematic 
review and meta-analysis (Study II), a population-based cohort study (Study III), and a 
population-based case-control study (Study IV).  
Epidemiological studies include both experimental and observational study designs, but this 
thesis only includes observational studies. The research questions under study are not feasible 
and unethical to examine in an experimental study (e.g., randomized clinical trial) because of 
exploration in etiology and limited prior evidence of preventive measures. The main 
observational study designs are cohort studies, case-control studies, cross-sectional studies, 
and ecologic studies. Cohort studies classify participants in a source population according to 
their exposure status and follow them over a certain period to assess disease incidence. Case-
control studies identify cases and controls from the same source population and classify them 
according to their exposure history. Observational studies can also be categorized as either 
prospective or retrospective studies. It is not straightforward to use these terms, but one 
recommendation is to use these terms to elucidate whether the outcome could influence the 
exposure information.116 Thus, prospective studies refer to studies where the outcome could 
not influence the exposure information and vice versa.  
Descriptive studies often describe the characteristics or demographics of a population. A 
descriptive study collects quantitative information for statistical analysis, and typically uses a 
cross-sectional design. Study I is a descriptive study of global incidence trends.  
 
Figure 12. Evidence level for research 
Systematic review and meta-analysis studies are regarded as the highest quality of evidence 
level in research by several researchers (Figure 12).117 These studies aim to include all 
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available and relevant studies on a specific topic by using a systematic and comprehensive 
search strategy. They also evaluate the studies’ quality and combine the results from different 
studies. In Study II, we identified published studies on smoking cessation and ESCC risk, 
assessed their validity, and analyzed the combined results.       
In Study III, registry-based data were used and data on medication use (exposure) were 
collected before the onset of ESCC (outcome), suggesting a prospective design. In Study IV, 
cases of ESCC (outcome) were confirmed before collecting exposure information via 
interview, making it a retrospective study design, and recall bias can be an issue. However, 
our study included both ESCC and EAC patients and clearly different risk factor patterns 
were revealed for these two diseases, which indicate the limited influence of recall bias.                       
6.1.2 Measure of disease  
6.1.2.1 Age-standardization  
Incidence rate is a measure of the occurrence of a disease, computing number of new cases in 
the background population during a specific time frame. Incidence rate is frequently 
presented as a number of cases per 100,000 person-years in a rare disease setting. 
To have a comparable disease burden in populations with different age structures, age-
standardization methods are often used. The direct method or indirect method can be applied 
for age-standardization. Generally, direct age-standardization is favored over the indirect 
method. For age groups (I), the direct method calculates age-specific rates (ri) in the target 
population with weights (wi) from a standard population, using this formula: 
𝐴𝐴𝐴𝐴𝐴𝐴 = ∑ (𝑟𝑟𝑖𝑖 × 𝑤𝑤𝑖𝑖)𝐼𝐼𝑖𝑖=1
∑ 𝑤𝑤𝑖𝑖
𝐼𝐼
𝑖𝑖=1
 
In Study I, we calculated ASR for each of the included countries during the study period, 
using the WHO World Standard Population (2000) as a reference, a most frequently used 
standard population. Therefore, the derived results for each population can be compared with 
other populations within this study and with other studies using the same reference.  
6.1.2.2 Age-period-cohort analysis 
The age-period-cohort model is a parametric statistical model that can summarize ESCC 
incidence rate trends over time. The complete age-period-cohort model can be written as in 
the formula bellow,118 with both linear components (𝑎𝑎, 𝑝𝑝, 𝑐𝑐) and non-linear components 
(𝑥𝑥𝐴𝐴𝑖𝑖 , 𝑥𝑥𝑃𝑃𝑃𝑃 , 𝑥𝑥𝐶𝐶𝐶𝐶):  
ln �𝑦𝑦
𝑛𝑛
� = 𝜇𝜇𝐿𝐿 + 𝛼𝛼𝐿𝐿𝑎𝑎 + 𝛽𝛽𝐿𝐿𝑝𝑝 + 𝛾𝛾𝐿𝐿𝑐𝑐 + � 𝜌𝜌𝐴𝐴𝑖𝑖𝑥𝑥𝐴𝐴𝑖𝑖𝑛𝑛𝑎𝑎−1
𝑖𝑖=1
+ � 𝜌𝜌𝑃𝑃𝑃𝑃𝑥𝑥𝑃𝑃𝑃𝑃+𝑛𝑛𝑝𝑝−1
𝑃𝑃=1
� 𝜌𝜌𝐶𝐶𝐶𝐶𝑥𝑥𝐶𝐶𝐶𝐶
𝑛𝑛𝑐𝑐−1
𝐶𝐶=1
 
The model assumes that no period effect (𝛽𝛽𝐿𝐿 = 0) could yield a longitudinal model and no 
cohort trends (𝛾𝛾𝐿𝐿 = 0) could lead to a cross-sectional model. As birth cohort (c) = time 
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period (p) - age (a), this model can be transferred into two two-factor models: age-cohort 
model and age-period model. The age-cohort model is generally preferred in cancer 
epidemiological settings, given that the exposures usually take a long time to influence the 
outcome, thus making the cohort better represent the pattern of exposure than period. Net 
drift represents the average annual percent change of incidence rate. Net drift equaling zero 
defines no changes over time, with proportional longitudinal and cross-sectional age curves. 
Local drift represents the annual percent change of incidence rate. Local drift equaling the net 
drift implies the same time trends in each age group. Using a reference period (or cohort), 
period rate ratios (or cohort rate ratios) can be estimated after adjusting for age and non-linear 
cohort effect (or non-linear period effect). Period rate ratios equaling one may imply 
constant time trends and that the cross-sectional age curve shows age incidence pattern in 
each period. Cohort rate ratios equaling one indicates that all local drifts equal zero and that 
the longitudinal age curve represents age incidence in each cohort. In Study I, all the above-
mentioned terms were computed and used to interpret the time trends changes in different 
countries.    
6.1.3 Systematic review and meta-analysis  
6.1.3.1 Aggregation bias 
Aggregation bias (or ecologic bias) occurs when we measure group outcomes based on 
means or rates of group exposure, rather than values of individual exposure. It is also 
common that meta-analyses compute the grouped results adjusting for the mean values of 
other covariates, which could distort the results. Aggregation bias, therefore, might exist in 
meta-analyses, and the aggregated results have to be interpreted with caution. In Study II, we 
performed several sensitivity analyses, all indicating the robustness of the results. The strong 
association between smoking cessation and decreased ESCC risk compared to continued 
smoking is also less likely to be affected by other covariates. Yet, careful interpretation of the 
results is still needed.    
6.1.3.2 Exclusion bias 
Exclusion bias (or selection bias) in systematic reviews might come from the inappropriate 
exclusion of studies, such as using an incomplete search strategy or exclusion of small sample 
size or low-quality studies, specific study type (e.g., case-control studies, or specific study 
population), and studies with less informative data. In Study II, we initially identified 15,009 
publication records using a predefined and comprehensive search strategy and we enrolled all 
available studies, regardless of their sample size, study quality, or study type. To evaluate 
bias from differences in study quality, we stratified the analyses according to different 
characteristics of studies. Less informative studies might bias the overall results; however, 
this should be limited because we only identified four such studies.  
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6.1.3.3 Publication bias 
Publication bias is a major source of bias in systematic reviews and it is usually related to 
other sources of bias, e.g., significance bias, study size bias, and suppression bias from 
sponsors. Such bias has to be carefully assessed before making conclusions. In Study II, we 
tested the publication bias using funnel plots, and Begg’s and Egger’s tests.116 None of these 
methods identified publication bias in the study, lending validity to the findings of the study.   
6.1.3.4 Heterogeneity  
Population heterogeneity and methodological heterogeneity are common in systematic 
reviews. Population heterogeneity derives from differences in the study region, population 
age and sex, or risk factors in the diseases. Methodological heterogeneity comes from 
differences in study design, measurement of exposures and outcomes, adjustment for 
covariates, and statistical methods. Heterogeneity was assessed using Cochran’s Q test and I2 
statistic in our study. Given the relatively large number of included studies, both subgroup 
analyses and meta-regression were applied to explore the source of heterogeneity, as well as 
the random-effects model which is usually more conservative than the fixed-effects model. 
Furthermore, quality scoring system and “move-one-out” sensitivity analysis were conducted, 
both of which support the robustness of the study results.   
6.1.4 Internal validity 
6.1.4.1 Selection bias 
Selection bias might occur due to problems in study subjects’ participation. A pitfall in 
selecting participants is neglecting those who are lost to follow up and those who are eligible 
for the study but do not participate, especially when their exposure and outcome patterns 
differ from those included. One type of selection bias is self-selection bias, e.g., patients 
exposed to the risk factor or with diseases are more likely to be involved in the study. In 
Study III, almost all metformin users in Sweden during the study period were included in the 
study. Non-metformin users were selected from the 8.4 million background population 
among about ten million national populations at that time. Disease status was obtained during 
the follow-up by linkage to national registries. Selection bias in that study should be less 
likely because of the complete follow-up of the cohort. In Study IV, the case-control study, a 
systematic sampling method (born on even dates) was applied to enroll half of all national 
ESCC cases, and controls were randomly selected from the national population registry. Both 
cases and controls had a rather high participation rate of 73%. In addition, a separate analysis 
showed no differences in baseline characteristics comparing non-participants and 
participants. Thus, selection bias should not strongly bias the results of Study IV.  
6.1.4.2 Information bias 
Information bias derives from measurement errors when collecting information for a study. 
Non-differential misclassification occurs when the misclassification of subjects’ exposure is 
unrelated to the status of the participants’ covariates, or disease. This error tends to 
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incorrectly turn the results to null values. Differential misclassification results from 
measurement errors that are not equal in the exposed (or diseased) and non-exposed (or non-
diseased) group and it could bias the results in any direction. Recall bias might influence the 
results of case-control studies when researchers try to collect exposure or covariates 
information, but differences in the reporting of information occur because of the case or 
control status of the participants. The direction of recall bias is unpredictable and can either 
exaggerate or underestimate the estimates. Therefore it should be avoided or limited in the 
study. Detection bias happens during the disease information collection process when the 
possibility of being detected for the disease under study differs in exposed and non-exposed 
participants. In Study III, information bias was avoided by using registry-based data, 
indicating a prospective collection of exposure information and almost 100% completeness of 
disease information. Recall bias can exist in Study IV for the case-control setting, but it 
should be limited because of the distinct differences in etiological patterns found for ESCC 
and EAC patients in the same study.           
6.1.4.3 Confounding  
Confounding factors (confounders) can explain parts of or all differences between the 
measure of the association and the measure of the effect that could be achieved in an ideal 
counterfactual setting.116 In other words, a confounder spuriously biases the exposure-
outcome association by influencing both the exposure and the outcome, without being in the 
causal pathway (i.e., not a mediator). Confounding needs to be considered in observational 
studies either in the study design phase (e.g., matching by a confounder in a cohort study, 
restricting the participants regarding the status of confounders) or during the statistical 
analysis process (e.g., adjustment and stratification). To counteract confounding in Study III, 
we matched metformin users with nonusers by age and sex, adjusted for some other 
confounders in the statistical model, and stratified the analyses by potential confounders. 
Although residual or unmeasured confounding might still exist, any confounding should not 
alter the identified association to null, as indicated in the rule-out analysis.  
6.1.4.4 Random error 
Another main methodological issue is random error (or chance variation), which is inverse to 
statistical precision. It derives from unexplained variations in statistical measurements or the 
sampling process from the so-called “super population”. A risk of random error is 
unavoidable, but we can reduce it by increasing the sample size and avoiding multiple testing. 
The precision is often estimated as CI or P values in statistical analysis. 95% CI is defined as, 
if repeatedly sampling from a “super-population” with different sample populations and 95% 
CIs are computed for each of the sample population, then at least 95% of these intervals 
include the true value of the “super-population”, providing no bias exists. Namely, there is 
95% confidence that the true value from the “super-population” is included. The P-value (or 
probability value) is derived from significance testing and tests the probability of attaining 
the current observed results assuming that the null hypothesis is correct. It is the possibility of 
detecting a difference in sample populations (reject the null hypothesis) when no difference 
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exists in the “super population” (null hypothesis is true) (Type I error). To reduce Type I 
errors, one may either lower the significance testing level or perform a multiple testing 
correction if multiple testing has been conducted. But both of these methods result in an 
increased chance of Type II error, which is defined as the possibility of not rejecting the null 
hypothesis when it is false. The studies included in this thesis did not use any of these two 
methods. Instead, we limited the predefined study hypothesis testing and only included 
covariates according to subject-matter knowledge.     
6.1.5 External validity  
External validity or generalizability concerns whether the findings from a study are valid also 
in other populations or settings. Representativeness is often considered as a hindrance of 
good internal validity, and without internal validity, it is impossible to even discuss external 
validity. Therefore, internal validity is often given priority rather than generalizability. Study 
II merits high generalizability since we included many populations in the world. Despite high 
internal validity, only the Swedish population was considered in Study III and IV, which may 
limit the external validity of these two studies to other populations, especially non-Western 
populations.    
6.1.6 Assessment of the performance of prediction models  
6.1.6.1 Discrimination  
Discrimination of a prediction model refers to the ability to discriminate those with the 
outcome from those without outcome. The discriminative ability can be assessed by the 
concordance (c) statistic, which is a rank-order statistic and identical to the AUC for binary-
outcome studies. Somers’ D statistic measures the direction and strength of predictions 
against observed outcomes, related to c statistic.114 In addition, the discrimination slope 
assesses the absolute difference between the average predicted probability with and without 
the outcome and is usually visualized as a box plot or histogram. In Study IV, we evaluated 
the risk prediction model using both AUC and Somers’ D statistic. Both the derivation model 
and the cross-validation model showed good discriminative abilities.            
6.1.6.2 Calibration  
Calibration is the agreement between predictions and observed outcomes within a certain 
period. A calibration plot is a common tool to assess the calibration of a risk prediction 
model, with predictions on the x-axis and observations on the y-axis. An ideal calibration plot 
should have a slope b of 1 and an intercept a of 0 (calibration-in-the-large, indicating if the 
model is systematically skewed). For binary outcome, albeit of being criticized as arbitrary 
grouping, the Hosmer-Lemeshow goodness-of-fit test is often applied to the plotted observed 
outcome by decile of predictions. However, calibration in Study IV could not be assessed due 
to the case-control study design and limited sample size of control participants, which makes 
it unfeasible to observe even one case during the next decades, given the low incidence rate 
of ESCC.  
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6.2 GENERAL DISCUSSION  
6.2.1 Study I 
Study I presented an overview of global incidence trends of ESCC by directly collecting data 
from 30 cancer registries in 20 countries. The incidence of ESCC in men had decreased in 
most of the 20 countries included in this study, although the rate was still high in Japan, 
France, and Hong Kong, China. The incidence of ESCC was lower in women than men and 
was stable or slightly decreased in women in most countries. However, an increasing trend 
was observed in women in Japan, the Netherlands, New Zealand, Norway, and Switzerland. 
Birth-cohort effects played a stronger determinant role in these countries, indicating potential 
etiological alterations. Age-period-cohort results suggested a further increasing incidence of 
ESCC in Japanese and Norwegian women in the coming decades. 
There is a need for cautious interpretation of temporal incidence trends. Changes over time 
regarding, e.g., diagnostic techniques, screening programs, or completeness of registration 
systems, might contribute. However, such changes should not explain the decreasing 
incidence rates identified in the study. A more probable reason for the decrease is changes in 
risk factor exposures, which is supported by the significant cohort effect from the age-period-
cohort analyses. Changes in smoking and alcohol consumption, the two main risk factors of 
ESCC, could contribute. The generally decreasing incidence of ESCC after the 1990s might 
be explained by the global smoking control activities since the 1980s and decreasing or stable 
prevalence of alcohol consumption.119-121 Switzerland has an increasing prevalence of 
smoking in women (from 21% in 1980 to 26% in 1998), which might explain the increased 
incidence of ESCC.119 In Japanese women, increased alcohol consumption has been reported, 
which could contribute to the increasing incidence.120 122 123  
Compared with previous ESCC incidence trends studies, this study is more updated, includes 
more registries, covers a longer period, and is based on data directly retrieved from the 
registries. The age-period-cohort analyses also provide etiological clues for future studies. 
This study did not have national registries for some countries, e.g., Japan, Spain, and the 
United Kingdom. In these countries, we merged regional registries. Unfortunately, we were 
unable to collect data from mainland China, which contributes almost half of all ESCC cases 
in the world. This study indicates that although smoking control activities may have 
contributed to the decreasing trends of ESCC, more efforts towards alcohol control are 
warranted, especially in women.                                 
6.2.2 Study II 
Study II revealed a substantially lower risk of ESCC in former smokers than in current 
smokers and a clear time-dependent association between smoking cessation and ESCC risk. 
Compared with current smokers, a decreased risk started five years after quitting smoking, 
and long-term smoking quitters (i.e., 20 years’ smoking cessation) had almost as low risk as 
never smokers.  
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Lower risk in former smokers than current smokers was also reported in a meta-analysis 
study of Japanese studies.124 Although without specifying the histological subtype of 
esophageal cancer, about 90% is ESCC in Japan.125 The geographic differences of ESCC risk 
could be partly justified by other risk factors (e.g., passive smoking, hot food and drinks, and 
pickled vegetables), which facilitate a high-risk baseline of ESCC in Asian countries. 
Quitting smoking alone might have a limited influence on decreasing the risk of ESCC in 
Asian populations.   
This study is merited by its extensive search strategy, which identified a large number of 
studies and participants. Detailed subgroup analyses and dose-response analyses were, 
therefore, possible. Nevertheless, heterogeneity was discovered for the included studies, 
which was mainly caused by differences in sex distribution, study quality, geographic region, 
and source of controls. Therefore, stratified analyses by these factors were carefully 
performed, and similar results suggest the robustness. Additionally, restriction by English 
publications might bias results in the study, but this should be a limited concern because 
language restriction was only performed at a late stage of the inclusion process and records in 
other languages were few. The gradually decreased ESCC risk following smoking cessation 
is biologically plausible, and this study reinforces the value of recommending abstinence 
from smoking.      
6.2.3 Study III 
With a large population-based national cohort, Study III addressed the hypothesis that 
metformin use decreases the risk of ESCC. Metformin users were about 32% less likely to be 
diagnosed with ESCC than their comparators from the background population.  
Previous studies have reported contradictory results regarding the association between 
metformin and ESCC risk. An increased risk of esophageal cancer associated with metformin 
use was reported in a case-control study from Taiwan (OR 2.84, 95% CI 0.99-8.18), whereas 
a decreased risk was suggested in a Taiwanese cohort study (HR 0.49, 95% CI 0.35-0.68) and 
a Dutch cohort study (HR 0.90, 95% CI 0.82-0.97).88 89 126 A few other studies did not reveal 
any association.86 87 127 A shared limitation of all these studies was that they did not separate 
ESCC from EAC, despite their distinct etiological patterns. The lack of adjustment for 
obesity in these studies probably introduced confounding because obesity is strongly 
associated with both diabetes (and thus metformin use) and EAC, whereas obesity is not a 
risk factor for ESCC and should therefore not confound the results of the present study.  
One could argue that diabetes diagnosis could bias the results, but no association has been 
found between diabetes and ESCC.128 129 Another concern might be bias from the use of 
insulin, which has been reported to increase the risk of esophageal cancer.126 Patients who 
receive insulin usually have more severe diabetes and are therefore less likely to receive 
metformin. However, any confounding by insulin should be limited, given that this study 
only included 2% of insulin users. Compared with the group using the lowest dose of 
metformin, the higher-dose groups had no clearly further risk reduction. This may indicate a 
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possible benefit of a low-dose medication, which is supported by the finding of a lower risk 
of ESCC in new metformin users than in ever users. However, we cannot exclude that such 
lower risk may be due to different drug exposures between metformin new users and ever 
users, i.e., different exposure to other anti-diabetes drugs (e.g., sulfonylurea), which may 
increase the risk of ESCC.   
Among the strengths of this study is the population-based cohort study design with long and 
complete follow-up using well-established registry data, which should reduce concerns about 
selection bias and information bias. The matched-cohort study design with competing risk 
analyses counteracted limit time-related bias. Yet, residual or unmeasured confounding (e.g., 
from dietary factors) possibly remains, although the rule-out analysis showed that such 
confounding should be limited. Finally, misclassification of metformin use may affect the 
association because we cannot know for sure that participants dispensed with metformin 
actually used the medication.     
6.2.4 Study IV 
In Western countries, routine endoscopic screening or surveillance of the general population 
for ESCC is not cost-effective or feasible. Instead, a prediction model could help select high-
risk individuals. With readily identifiable predictors, this study constructed a full model and a 
simple model that had a good ability to predict an individual’s absolute five-year risk of 
ESCC. 
It is the first prediction model on ESCC risk in a Western population and is based on a 
national Swedish case-control study of high internal validity. However, several limitations of 
the model warrant attention. Recall bias cannot be completely excluded, although one could 
dispute this bias by the different risk factors profiles found for EAC in the same study. Some 
uncertainties in the precision of predicted risk estimates remained due to limited power in 
some subgroups. Despite good interval validation of the developed model, external validation 
using an independent population was not conducted. Thus, overfitting or overestimation is 
possible and the calibration of the model is difficult to evaluate.130 Therefore, we have 
recently conducted a prediction model using two large independent cohorts (not included in 
this thesis), the Nord-Trøndelag Health Study (HUNT, as model derivation cohort), and the 
UK Biobank cohort (as external validation cohort). To accurately estimate the ESCC risk, we 
applied a competing risk model (the Fine and Gray model). The final model included similar 
predictors as those used in the present study, i.e., age, sex, smoking, alcohol, but also body 
mass index. The model had an AUC of 0.77 (95% CI 0.67-0.87) for a 15-year risk and 0.76 
(95% CI 0.59-0.93) for a five-year risk in HUNT. External validation in UK Biobank found 
an AUC of 0.70 (95% CI 0.65-0.76). The Hosmer and Lemeshow goodness-of-fit test 
indicated a good fit (P >0.05 for all models), and the calibration plots are shown in 
Supplementary Figure 1.  
This easy-to-use risk prediction model of ESCC could be useful for healthcare providers and 
public health decision-makers. The model can estimate an individual’s risk of ESCC within 
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specific years. Stratifying populations into different risk groups may enable more cost-
effective screening and surveillance programs, which could promote the detection of 
premalignant conditions and early-stage ESCC, thus may help reduce deaths from this 
aggressive tumor.           
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7 CONCLUSIONS 
• The incidence of ESCC has decreased in most of the examined countries, but 
increasing trends were found in women in a few countries. Birth-cohort effects were 
important for the changes, indicating a need for preventive measures.  
• Smoking cessation time-dependently reduced ESCC risk compared to continued 
smoking, and the risk reduction started after >5 years of smoking cessation and 
approached the level of never smokers after >20 years. 
• Metformin use may decrease the risk of ESCC. 
• A model based on four readily available predictors (age, sex, tobacco smoking, and 
alcohol use) showed good discriminative accuracy in predicting the absolute five-year 
risk of ESCC in a Western population.  
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8 FUTURE PERSPECTIVES 
The decreasing incidence of ESCC is probably, at least partly, due to the reduced prevalence 
of tobacco smoking. Avoiding tobacco and alcohol overconsumption should also be 
emphasized in women. Etiological patterns of ESCC are more complex in Eastern countries, 
indicating a need for more research in these populations. Current knowledge of molecular 
characterization in ESCC is limited. Recent developments in molecular detecting techniques 
and methodological improvements could facilitate a deeper insight into the molecular 
mechanisms of ESCC, e.g., by omics studies such as genomics, microbolomics, and 
metabolomics.  
Another potential primary prevention of ESCC might be chemoprevention, such as 
medication with metformin, NSAIDs/aspirin or statins, albeit more observational research in 
other populations and randomized clinical trials are required.     
Early detection of ESCC could be possible by screening or surveillance of high-risk 
populations. More practical and feasible screening approaches are needed. Although ESCC 
risk prediction models have been developed to stratify populations into high- or low- risk 
groups, none of them have been externally validated. A well-established risk prediction 
model is still expected. A further investigation of biomarkers, such as alterations of serum 
microRNAs before ESCC diagnosis, may improve the risk prediction.  
Additionally, more clinical studies regarding standardized treatments and follow-up patterns 
of the esophageal squamous dysplasia (ESCC precursor) are essential for an established and 
valid clinical guideline.      
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9 POPULAR SCIENCE SUMMARIES 
9.1 Popular science summary 
Esophageal cancer is a deadly cancer, with more than 80% of esophageal cancer patients died 
within five years after diagnosis. Esophageal squamous cell carcinoma (ESCC) is the main 
subtype of esophageal cancer. Because patients with early-stage tumors rarely present any 
typical symptoms, more than half of the ESCC patients are diagnosed at a late stage when the 
tumor is too advanced to allow curative treatment. Prevention and diagnosis at an earlier 
stage would substantially reduce the mortality in ESCC. Thus this thesis aims to provide a 
better understanding of possible measures for such prevention and early detection.   
In Study I, we collected data on ESCC from 30 cancer registries in 20 countries between 
1970 and 2015. We calculated the occurrence rate in different countries using the age-
standardized method, which makes the rates comparable. For the year 2012, Japan had the 
highest occurrence of ESCC. During the past decades, most countries showed decreasing 
trends of ESCC rates, although increasing rates were found in women in Japan, the 
Netherlands, New Zealand, Norway, and Switzerland. We examined the reasons behind the 
change in the rates and found that the increased rates in women in these countries could be 
due to the increased use of smoking and alcohol drinking, or other factors related to an 
unhealthy lifestyle.  
Study II is a pooled analysis of studies that have investigated the association between 
smoking and ESCC. By searching in databases, we identified 41 relevant studies among 
15,009 publications. Compared with never smokers, current smokers had a four times higher 
risk of ESCC, while former smokers had a two times higher risk of ESCC. The benefits of 
stopping smoking were strong in Western populations but weak in the Asian populations. 
After smoking cessation, the risk of ESCC decreased by 41% after five-to-nine years, 58% 
after 10-20 years, and 66% after over 20 years. The latter category had a risk similar to never 
smokers.         
In Study III, we assessed whether the use of metformin, a medicine commonly used to treat 
diabetes, prevents ESCC. We linked data from the Swedish Prescribed Drug Registry, Patient 
Registry, Cancer Registry, and Cause of Death Registry in 2005-2015. Among 8.4 million 
participants, 411,603 (5%) used metformin. Compared with ten times as many participants 
who did not use metformin, those who used metformin had a 32% decreased risk of 
developing ESCC.  
In Study IV, we compared 167 ESCC patients with 820 control participants between 1995 
and 1997 in Sweden. All participants were interviewed and their lifestyle information was 
collected. Then we developed a model that can be used to estimate an individual’s absolute 
risk of developing ESCC during the next five years. According to information on age, sex, 
tobacco smoking, abuse of alcohol, years of education, duration of living with a partner, and 
place of residence during childhood, a model worked well in identifying ESCC patients. 
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Another simpler model was developed with only four factors (age, sex, tobacco smoking, and 
abuse of alcohol), which was almost as good as the first model. A calculator is available 
online for individuals who are interested in knowing their own risk of ESCC in the next five 
years.  
In summary, although the occurrence of ESCC is decreasing, it remains common cancer 
globally. It is possible to prevent ESCC by quitting smoking. Using metformin might also 
reduce the ESCC risk, but this result has to be confirmed in future studies. A simple risk 
prediction model can help identify people at high risk of developing ESCC and may help 
them seek healthcare earlier and detect ESCC at an early and curable stage.        
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9.2 Populärvetenskaplig sammanfattning 
Matstrupscancer är en dödlig cancer och mer än 80 % av patienter dör inom fem år efter 
diagnosen. Skivepitelcancer (ESCC) är den vanligaste typen av matstrupscancer. Eftersom 
patienter med tumör i tidigt stadium sällan uppvisar symtom, diagnostiseras de flesta ESCC-
patienter i ett sent skede när tumören redan är för avancerad för att möjliggöra botande 
behandling. Diagnos i ett tidigare skede skulle minska dödligheten i ESCC betydligt. Denna 
avhandling syftar till att ge en bättre förståelse för möjliggöra förebyggande åtgärder och 
tidigare upptäckt. 
I studie I använde vi 30 cancerregister från 20 länder och samlade in data om patienter med 
ESCC mellan 1970 och 2015. Sedan beräknade vi förändringar i förekomst i olika länder med 
hjälp av en åldersstandardiserad metod, vilket gör länderna dem jämförbara. År 2012 hade 
Japan den högsta förekomsten av ESCC. Under de senaste decennierna visade de flesta 
länderna minskade trender för ESCC även om ökande frekvenser hittades hos kvinnor i 
Japan, Nederländerna, Nya Zeeland, Norge och Schweiz. Vi undersökte orsakerna till 
förändringarna över tid och fann att den ökade förekomsten i vissa länder kan bero på ökad 
rökning, alkoholkonsumtion eller andra ohälsosamma livsstilsfaktorer. 
Studie II är en analys av 41 publicerade artiklar om sambandet mellan rökning och ESCC. 
Dessa studier fann vi genom att söka i databaser bland 15,009 publikationer. Jämfört med 
personer som aldrig rökt hade nuvarande rökare fyra gånger högre risk för ESCC, medan 
tidigare rökare hade två gånger högre risk för ESCC. Fördelarna med att sluta röka var starka 
i västerländska befolkningar men svaga i asiatiska befolkningarna. När nuvarande rökare 
slutade röka minskade risken för ESCC med 41 % efter fem till nio år, 58 % efter tio till tjugo 
år och 66 % efter över 20 år. Den senare kategorin hade en nästan lika låg risk för ESCC som 
de som aldrig rökt. 
I studie III undersökte vi om användning av metformin, ett läkemedel som ofta används för 
att behandla diabetes, minskar risken för ESCC. Vi använde data från Läkemedelsregistret, 
Patientregistret, Cancerregistret och Dödsorsaksregistret mellan åren 2005 och 2015. Av 8.4 
miljoner personer använde 411,603 (5 %) metformin. Jämfört med tio gånger så många 
deltagare som inte använde metformin, hade de som använde metformin 32 % minskad risk 
för att utveckla ESCC. 
I studie IV deltog 167 ESCC-patienter och 820 kontrollpersoner från befolkningen i en studie 
som via intervjuer samlade in uppgifter under åren 1995 och 1997 i Sverige. Med hjälp av 
informationen utvecklade vi en modell som kan användas för att beräkna individers risk för 
att utveckla ESCC under de kommande fem åren beroende på ålder, kön, tobaksrökning, 
missbruk av alkohol, utbildningsår, sammanboende med en partner och bostadområde under 
barndomen. En annan enklare modell utvecklades också med bara fyra faktorer (ålder, kön, 
tobaksrökning och missbruk av alkohol). Modellerna var bra på att utkristallisera 
högriskindivider, och den enkla modellen var nästan lika bra som den första modellen. En 
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kalkylator är tillgänglig online för personer som är intresserade av att få veta till sin egen risk 
för ESCC. 
Sammanfattningsvis är ESCC en globalt sett ganska vanlig cancer även om dess förekomst 
lyckligtvis är på nedgående. Det är möjligt att minska risken för ESCC genom att sluta röka. 
Att ta läkemedlet metformin kan också minska ESCC-risken, men detta resultat måste 
bekräftas i framtida studier. Modellerna för riskprognos kan användas för att identifiera 
personer med hög risk för ESCC och kan hjälpa dessa att söka vård tidigt och därmed 
upptäcka ESCC i ett tidigare och botbart skede. 
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9.3 科普性总结 
食管癌死亡率极高，80%以上的患者的生存时间短于五年。食管鳞癌是其最主要的亚
型。鉴于肿瘤早期症状隐匿，绝大多数食管鳞癌患者在被诊断出来时已是中晚期，失
去了根治的机会。因此，早期发现并预防食管鳞癌是降低其死亡率的重要策略。本论
文旨在探寻其可行的预防和早发现措施。 
第一部分研究中，我们收集了全球 20个国家的 30个癌症统计局在 1970 年至 2015年
间的食管鳞癌发病数据，用年龄标准化方法计算发病率用于不同国家地区间的比较。
研究发现，2012年，日本在所有纳入国家中发病率最高。在过去的几十年中，大多
数国家的食管癌发病率呈下降趋势。然而，日本、荷兰、新西兰、挪威和瑞士的女性
食管鳞癌发病率却呈现上升趋势。研究发现这些国家的女性发病率上升可能与增加的
吸烟，饮酒或其他不健康生活方式有关。 
第二部分研究是针对戒烟和食管鳞癌相关性开展的对已发表研究的汇总分析。通过搜
索相关数据库，我们从 15009篇文章中纳入了 41个符合要求的研究。我们发现，目
前吸烟者较从不吸烟者患食管鳞癌的风险高四倍，而过去吸烟者较从不吸烟者患食管
鳞癌的风险高两倍。西方人戒烟后达到的降低食管鳞癌的风险收益比亚洲人更高。若
目前吸烟者戒烟，那么其在五至九年内发生食管鳞癌的风险将下降 41%，十年至二十
年内的风险下降 58%，二十年后更是下降 66%达到与从不吸烟者相似的风险。 
第三部分研究中，我们旨在评估二甲双胍（一种治疗糖尿病的常见药物）在预防食管
鳞癌发生中的作用。我们收集了在 2005年至 2015年期间瑞典统计局的相关数据，包
其主要来源于处方药注册统计局，患者统计局，癌症统计局和死因统计局。在 840万
人群中，有 411603（5%）瑞典人使用过二甲双胍。研究发现，使用二甲双胍的人患
食管鳞癌的风险比不使用该药物的人低 32%。 
第四部分研究中，我们对比了 1995至 1997年期间的 167例食管鳞癌患者和 820例健
康个体（非食管鳞癌患者），采访并收集其相关信息。我们利用这组数据建立了一个
模型用于评估个体五年内发生食管鳞癌的可能性。根据年龄，性别，吸烟史，饮酒
史，受教育年限，与伴侣共同生活的时间及童年期间的居住地等信息，该模型能够较
好地预测食管鳞癌的发生。同时，我们仅用年龄，性别，吸烟史和饮酒史，建立了一
个简单模型，该模型同样具有良好的预测效果。任何感兴趣了解自己相关风险的人可
以使用我们的在线计算器进行估算。 
综上所述，虽然食管鳞癌的发病率在下降，它仍然是目前最常见的肿瘤之一。戒烟可
以降低食管鳞癌的发生风险。而服用二甲双胍类药物也可能会预防食管鳞癌的发生，
但是该结论还需要被更多的研究加以证实。本文建立的风险预测模型可用于筛选出患
食管鳞癌的高风险人群，有望帮助他们尽早发现食管鳞癌并接受治疗。 
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9.4 Résumé des sciences populaires 
Le cancer de l’œsophage est un cancer mortel et plus de 80% des patients meurent dans les 
cinq ans suivant un diagnostic. Le carcinome épidermoïde de l’œsophage (ESCC) est le 
principal sous-type de cancer de l’œsophage. Comme les patients atteints de tumeurs à un 
stade précoce présentent rarement des symptômes typiques, plus de la moitié des patients 
ESCC sont diagnostiqués à un stade tardif, lorsque la tumeur est trop avancée pour permettre 
un traitement curatif. Vue que la prévention et le diagnostic à un stade précoce réduiraient la 
mortalité dans les ESCC, cette thèse vise à mieux comprendre les mesures possibles pour la 
prévention et la détection d’ESCC. 
Dans l’étude I, nous avons collecté des données sur l’ESCC dans 30 registres du cancer dans 
20 pays et collectées entre 1970 et 2015. Nous avons ensuite calculé le taux d’incidence dans 
différents pays en utilisant la méthode standardisée par l’âge, ce qui rend les taux 
comparables. Pour l’année 2012, le Japon avait l’incidence d’ESCC la plus élevée. Au cours 
des dernières décennies, le taux d’ESCC a eu une tendance à diminuer dans la plupart des 
pays, bien qu’on ait constaté des taux croissants chez les femmes au Japon, aux Pays-Bas, La 
Nouvelle-Zélande, la Norvège et la Suisse. Nous avons examiné les raisons de cette 
augmentation et avons constaté que l’augmentation du taux d’ESCC chez les femmes de ces 
pays pourrait être due à l’augmentation du taux de tabagisme, de consommation d’alcool ou 
d’autres modes de vie malsains. 
L’étude II est une analyse groupée d’études qui ont examiné l’association entre le tabagisme 
et l’ESCC. En recherchant dans les bases de données, nous avons identifié 41 études 
pertinentes parmi 15,009 publications. Par rapport aux personnes n’ayant jamais fumé, les 
fumeurs actuels présentaient un risque quatre fois plus élevé d’ESCC, tandis que les anciens 
fumeurs présentaient un risque deux fois plus élevé d’ESCC. Les avantages de l’arrêt du 
tabagisme étaient importants dans les populations occidentales mais faibles dans les 
populations asiatiques. Lorsque les fumeurs actuels arrêtent de fumer, le risque d’ESCC 
diminue de 41% après cinq à neuf ans, de 58% après dix à vingt ans et de 66% après plus de 
20 ans. Cette dernière catégorie présentait un risque semblable à celui des personnes n’ayant 
jamais fumé. 
Dans l’étude III, nous avons cherché à évaluer si l’utilisation de la metformine, un 
médicament utilisé pour traiter le diabète, empêche l’ESCC. Nous avons couplé les données 
de l’année 2005 à l’année 2015 du Registre Suédois des Médicaments Prescrits, du Registre 
des Patients, du Registre du Cancer et du Registre des Causes de Décès. Parmi les 8.4 
millions de participants, 411,603 (5%) ont utilisé la metformine. Ils présentaient une 
diminution de 32% du risque d’ESCC, comparativement à dix fois plus de participants qui 
n’utilisaient pas la metformine.  
L’étude IV comparé 167 patients d’ESCC et 820 participants témoins entre 1995 et 1997 en 
Suède. Tous les participants ont été interviewés pour recueillir des informations. À partir de 
ces informations, nous avons développé un modèle de prédiction pour estimer le risque 
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absolu de développer une ESCC au cours des cinq prochaines années. Basé sur des données 
d’âge, de sexe, de tabagisme, d’abus d’alcool, d’années d’éducation, de durée de vie avec un 
partenaire et de lieu de résidence pendant l’enfance, le modèle a bien fonctionné pour 
identifier les patients présentant un ESCC. Un autre modèle plus simple comportant 
seulement quatre facteurs (âge, sexe, tabagisme et abus d’alcool) a également été développé, 
qui était presque aussi efficace que le premier modèle. Une calculatrice est disponible en 
ligne pour les personnes qui souhaitent connaître leur propre risque de développer une ESCC. 
En résumé, bien que l’occurence de l’ESCC diminue, il reste un cancer commun à l’échelle 
mondiale. Il est possible de prévenir l’ESCC en cessant de fumer. La prise de metformine 
pourrait également réduire le risque d’ESCC, mais ce résultat doit être confirmé dans des 
études futures. Le modèle de prédiction du risque mis en point pourrait être utilisé pour 
identifier la population à risque élevé de développer une ESCC, qui seront encouragées à 
consulter un médecin plus tôt et à faire diagnostiquer leur ESCC à un stade précoce et 
curable. 
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12 SUPPLEMENTARY DOCUMENTS 
Supplementary Table 1a. Cancer staging categories for ESCC  
Category Criteria 
T category 
TX Tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis High-grade dysplasia, defined as malignant cells confined by the basement membrane 
T1 Tumor invades the lamina propria, muscularis mucosae, or submucosa 
T1a Tumor invades the lamina propria or muscularis mucosae 
T1b Tumor invades the submucosa 
T2 Tumor invades the muscularis propria 
T3 Tumor invades adventitia 
T4 Tumor invades adjacent structures 
T4a Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum 
T4b Tumor invades other adjacent structures, such as aorta, vertebral body, or trachea 
N category 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1–2 regional lymph nodes 
N2 Metastasis in 3–6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
M category 
M0 No distant metastasis 
M1 Distant metastasis 
G category 
GX Differentiation cannot be assessed 
G1 
Well-differentiated. Prominent keratinization with pearl formation and a minor component 
of nonkeratinizing basal-like cells. Tumor cells are arranged in sheets, and mitotic counts 
are low 
G2 Moderately differentiated. Variable histologic features, ranging from parakeratotic to poorly keratinizing lesions. Generally, pearl formation is absent 
G3‡ 
Poorly differentiated. Consists predominantly of basal-like cells forming large and small 
nests with frequent central necrosis. The nests consist of sheets or pavement-like 
arrangements of tumor cells, and occasionally are punctuated by small numbers of 
parakeratotic or keratinizing cells 
L category* 
LX Location unknown 
Upper Cervical esophagus to lower border of azygos vein 
Middle Lower border of azygos vein to lower border of inferior pulmonary vein 
Lower Lower border of inferior pulmonary vein to stomach, including esophagogastric junction 
‡, if further testing of “undifferentiated” cancers reveals a squamous cell component, or if after further 
testing they remain undifferentiated, categorize as squamous cell carcinoma G3; *, location is defined by 
epicenter of esophageal tumor. 
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Supplementary Table 1b. Clinical (cTNM) stage groups for ESCC 
cStage group cT cN cM 
0 Tis N0 M0 
I T1 N0–1 M0 
II T2 N0–1 M0 
T3 N0 M0 
III T3 N1 M0 
T1–3 N2 M0 
IVA T4 N0–2 M0 
T1–4 N3 M0 
IVB T1–4 N0–3 M1 
 
 
Supplementary Table 1c. Pathologic (pTNM) stage groups for ESCC 
pStage group pT pN pM pGrade pLocation 
0 Tis N0 M0 N/A Any 
IA T1a N0 M0 G1, X Any 
IB T1b N0 M0 G1, X Any 
T1 N0 M0 G2–3 Any 
T2 N0 M0 G1 Any 
IIA T2 N0 M0 G2–3, X Any 
T3 N0 M0 Any Lower 
T3 N0 M0 G1 Upper/middle 
IIB T3 N0 M0 G2–3 Upper/middle 
T3 N0 M0 X Any 
T3 N0 M0 Any X 
T1 N1 M0 Any Any 
IIIA T1 N2 M0 Any Any 
T2 N1 M0 Any Any 
IIIB T4a N0–1 M0 Any Any 
T3 N1 M0 Any Any 
T2–3 N2 M0 Any Any 
IVA T4a N2 M0 Any Any 
T4b N0–2 M0 Any Any 
T1–4 N3 M0 Any Any 
IVB T1–4 N0–3 M1 Any Any 
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Supplementary Figure 1. Calibration of observed cumulative proportion of ESCC cases 
and predicted cumulative risk of ESCC in HUNT and UK Biobank cohort 
             
Note a denotes the intercept; b denote the slope  
 
 
 
 
 
 
 
